{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:25:43Z","timestamp":1793388343698,"version":"4.5.0"},"reference-count":388,"publisher":"Bentham Science Publishers Ltd.","issue":"6","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"funder":[{"DOI":"10.13039\/501100001824","name":"Grant Agency of the Czech Republic","doi-asserted-by":"publisher","award":["23-06301J"],"award-info":[{"award-number":["23-06301J"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Cancer Research","award":["LX22NPO5102"],"award-info":[{"award-number":["LX22NPO5102"]}]},{"name":"National Institute for Neurological Research","award":["LX22NPO5107"],"award-info":[{"award-number":["LX22NPO5107"]}]},{"name":"National Institute of virology and bacteriology","award":["LX22NPO5103"],"award-info":[{"award-number":["LX22NPO5103"]}]},{"DOI":"10.13039\/501100001823","name":"European Union - Next Generation EU from the Ministry of Education, Youth and Sports of the Czech Republic","doi-asserted-by":"publisher","award":["TN02000109"],"award-info":[{"award-number":["TN02000109"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Neurodegenerative disease (ND) incidence has recently increased due to improved life expectancy. Alzheimer's (AD) or Parkinson's disease (PD) are the most prevalent NDs. Both diseases are poly genetic, multifactorial and heterogenous. Preventive medicine, a healthy diet, exercise, and controlling comorbidities may delay the onset. After the diseases are diagnosed, therapy is needed to slow progression. Recent studies show that local, peripheral and age-related inflammation accelerates NDs' onset and progression. Patients with autoimmune disorders like inflammatory bowel disease (IBD) could be at higher risk of developing AD or PD. However, no increase in ND incidence has been reported if the patients are adequately diagnosed and treated. Autoantibodies against abnormal tau, \u03b2 amyloid and \u03b1- synuclein have been encountered in AD and PD and may be protective. This discovery led to the proposal of immune-based therapies for AD and PD involving monoclonal antibodies, immunization\/vaccines, pro-inflammatory cytokine inhibition and anti-inflammatory cytokine addition.\nAll the different approaches have been analysed here. Future perspectives on new therapeutic strategies for both disorders are concisely examined.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x22666231017141636","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T19:01:39Z","timestamp":1697742099000},"page":"1080-1109","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Inflammation, Autoimmunity and Neurodegenerative Diseases,\nTherapeutics and Beyond"],"prefix":"10.2174","volume":"22","author":[{"given":"Jenny Valentina","family":"Garmendia","sequence":"first","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc,\nThe Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Valentina","family":"De Sanctis","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc,\nThe Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viswanath","family":"Das","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc,\nThe Czech Republic"},{"name":"The Czech Advanced Technology and Research Institute (Catrin), Palacky University, Olomouc,\nThe Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendran","family":"Annadurai","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc,\nThe Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari\u00e1n","family":"Hajduch","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc,\nThe Czech Republic"},{"name":"The Czech Advanced Technology and Research Institute (Catrin), Palacky University, Olomouc,\nThe Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Bautista","family":"De Sanctis","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc,\nThe Czech Republic"},{"name":"The Czech Advanced Technology and Research Institute (Catrin), Palacky University, Olomouc,\nThe Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.282.5391.1079","volume":"282","author":"Price D.L.","year":"1998","unstructured":"Price D.L.; Sisodia S.S.; Borchelt D.R.; Genetic neurodegenerative diseases: the human illness and transgenic models. Science  1998,282(5391),1079-1083","journal-title":"Science"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"MacDonald M.","year":"1993","unstructured":"MacDonald M.; A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell  1993,72(6),971-983","journal-title":"Cell"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41576-023-00592-y","volume":"24","author":"Ak\u00e7imen F.","year":"2023","unstructured":"Ak\u00e7imen F.; Lopez E.R.; Landers J.E.; Nath A.; Chi\u00f2 A.; Chia R.; Traynor B.J.; Amyotrophic lateral sclerosis: Translating genetic discoveries into therapies. Nat Rev Genet  2023,24(9),642-658","journal-title":"Nat Rev Genet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3390\/cimb45020094","volume":"45","author":"Papiri G.","year":"2023","unstructured":"Papiri G.; D\u2019Andreamatteo G.; Cacchi\u00f2 G.; Alia S.; Silvestrini M.; Paci C.; Luzzi S.; Vignini A.; Multiple sclerosis: Inflammatory and neuroglial aspects. Curr Issues Mol Biol  2023,45(2),1443-1470","journal-title":"Curr Issues Mol Biol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41582-023-00801-6","volume":"19","author":"Klotz L.","year":"2023","unstructured":"Klotz L.; Antel J.; Kuhlmann T.; Inflammation in multiple sclerosis: Consequences for remyelination and disease progression. Nat Rev Neurol  2023,19(5),305-320","journal-title":"Nat Rev Neurol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.neurol.2021.11.009","volume":"178","author":"Balcerac A.","year":"2022","unstructured":"Balcerac A.; Louapre C.; Genetics and familial distribution of multiple sclerosis: A review. Rev Neurol  2022,178(6),512-520","journal-title":"Rev Neurol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"5789","DOI":"10.3390\/molecules25245789","volume":"25","author":"Breijyeh Z.","year":"2020","unstructured":"Breijyeh Z.; Karaman R.; Comprehensive review on Alzheimer\u2019s disease: Causes and treatment. Molecules  2020,25(24),5789","journal-title":"Molecules"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1503\/cmaj.151179","volume":"188","author":"Rizek P.","year":"2016","unstructured":"Rizek P.; Kumar N.; Jog M.S.; An update on the diagnosis and treatment of Parkinson disease. CMAJ  2016,188(16),1157-1165","journal-title":"CMAJ"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7934442","volume":"2022","author":"Aborode A.T.","year":"2022","unstructured":"Aborode A.T.; Pustake M.; Awuah W.A.; Alwerdani M.; Shah P.; Yarlagadda R.; Ahmad S.; Silva C.I.F.; Chandra A.; Nansubuga E.P.; Abdul-Rahman T.; Mehta A.; Ali O.; Amaka S.O.; Zu\u00f1iga Y.M.H.; Shkodina A.D.; Inya O.C.; Shen B.; Alexiou A.; Targeting oxidative stress mechanisms to treat Alzheimer\u2019s and Parkinson\u2019s disease: A critical review. Oxid Med Cell Longev  2022,2022,1-9","journal-title":"Oxid Med Cell Longev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00335-016-9637-8","volume":"27","author":"Gorl\u00e9 N.","year":"2016","unstructured":"Gorl\u00e9 N.; Van Cauwenberghe C.; Libert C.; Vandenbroucke R.E.; The effect of aging on brain barriers and the consequences for Alzheimer\u2019s disease development. Mamm Genome  2016,27(7-8),407-420","journal-title":"Mamm Genome"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"15132","DOI":"10.18632\/oncotarget.23738","volume":"9","author":"Dai M.H.","year":"2018","unstructured":"Dai M.H.; Zheng H.; Zeng L.D.; Zhang Y.; The genes associated with early-onset Alzheimer\u2019s disease. Oncotarget  2018,9(19),15132-15143","journal-title":"Oncotarget"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/CIA.S200109","volume":"14","author":"Sumirtanurdin R.","year":"2019","unstructured":"Sumirtanurdin R.; Thalib A.Y.; Cantona K.; Abdulah R.; Effect of genetic polymorphisms on Alzheimer\u2019s disease treatment outcomes: An update. Clin Interv Aging  2019,14,631-642","journal-title":"Clin Interv Aging"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s42003-022-03287-y","volume":"5","author":"Sarnowski C.","year":"2022","unstructured":"Sarnowski C.; Ghanbari M.; Bis J.C.; Logue M.; Fornage M.; Mishra A.; Ahmad S.; Beiser A.S.; Boerwinkle E.; Bouteloup V.; Chouraki V.; Cupples L.A.; Damotte V.; DeCarli C.S.; DeStefano A.L.; Djouss\u00e9 L.; Fohner A.E.; Franz C.E.; Kautz T.F.; Lambert J.C.; Lyons M.J.; Mosley T.H.; Mukamal K.J.; Pase M.P.; Portilla Fernandez E.C.; Rissman R.A.; Satizabal C.L.; Vasan R.S.; Yaqub A.; Debette S.; Dufouil C.; Launer L.J.; Kremen W.S.; Longstreth W.T.; Ikram M.A.; Seshadri S.; Meta-analysis of genome-wide association studies identifies ancestry-specific associations underlying circulating total tau levels. Commun Biol  2022,5(1),336","journal-title":"Commun Biol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12264-016-0055-4","volume":"32","author":"Su F.","year":"2016","unstructured":"Su F.; Bai F.; Zhang Z.; Inflammatory cytokines and Alzheimer\u2019s disease: A review from the perspective of genetic polymorphisms. Neurosci Bull  2016,32(5),469-480","journal-title":"Neurosci Bull"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s43042-020-00056-6","volume":"21","author":"Ulhaq Z.S.","year":"2020","unstructured":"Ulhaq Z.S.; Garcia C.P.; Inflammation-related gene polymorphisms associated with Parkinson\u2019s disease: An updated meta-analysis. Egypt J Med Hum Genet  2020,21(1),14","journal-title":"Egypt J Med Hum Genet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13195-022-01159-5","volume":"15","author":"Li X.","year":"2023","unstructured":"Li X.; Zhang D.F.; Bi R.; Tan L.W.; Chen X.; Xu M.; Yao Y.G.; Convergent transcriptomic and genomic evidence supporting a dysregulation of CXCL16 and CCL5 in Alzheimer\u2019s disease. Alzheimers Res Ther  2023,15(1),17","journal-title":"Alzheimers Res Ther"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41531-021-00196-5","volume":"7","author":"Pedersen C.C.","year":"2021","unstructured":"Pedersen C.C.; Lange J.; F\u00f8rland M.G.G.; Macleod A.D.; Alves G.; Maple-Gr\u00f8dem J.; A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson\u2019s disease. NPJ Parkinsons Dis  2021,7(1),54","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1073\/pnas.1821778116","volume":"116","author":"Hollenbach J.A.","year":"2019","unstructured":"Hollenbach J.A.; Norman P.J.; Creary L.E.; Damotte V.; Montero-Martin G.; Caillier S.; Anderson K.M.; Misra M.K.; Nemat-Gorgani N.; Osoegawa K.; Santaniello A.; Renschen A.; Marin W.M.; Dandekar R.; Parham P.; Tanner C.M.; Hauser S.L.; Fernandez-Vi\u00f1a M.; Oksenberg J.R.; A specific amino acid motif of HLA-DRB1 mediates risk and interacts with smoking history in Parkinson\u2019s disease. Proc Natl Acad Sci  2019,116(15),7419-7424","journal-title":"Proc Natl Acad Sci"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41531-021-00231-5","volume":"7","author":"Yu E.","year":"2021","unstructured":"Yu E.; Ambati A.; Andersen M.S.; Krohn L.; Estiar M.A.; Saini P.; Senkevich K.; Sosero Y.L.; Sreelatha A.A.K.; Ruskey J.A.; Asayesh F.; Spiegelman D.; Toft M.; Viken M.K.; Sharma M.; Blauwendraat C.; Pihlstr\u00f8m L.; Mignot E.; Gan-Or Z.; Fine mapping of the HLA locus in Parkinson\u2019s disease in Europeans. NPJ Parkinsons Dis  2021,7(1),84","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00401-021-02268-5","volume":"141","author":"Harms A.S.","year":"2021","unstructured":"Harms A.S.; Ferreira S.A.; Romero-Ramos M.; Periphery and brain, innate and adaptive immunity in Parkinson\u2019s disease. Acta Neuropathol  2021,141(4),527-545","journal-title":"Acta Neuropathol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1119315","DOI":"10.3389\/fimmu.2023.1119315","volume":"14","author":"Yi M.","year":"2023","unstructured":"Yi M.; Li J.; Jian S.; Li B.; Huang Z.; Shu L.; Zhang Y.; Quantitative and causal analysis for inflammatory genes and the risk of Parkinson\u2019s disease. Front Immunol  2023,14,1119315","journal-title":"Front Immunol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","volume":"37","author":"Abbott N.J.","year":"2010","unstructured":"Abbott N.J.; Patabendige A.A.K.; Dolman D.E.M.; Yusof S.R.; Begley D.J.; Structure and function of the blood\u2013brain barrier. Neurobiol Dis  2010,37(1),13-25","journal-title":"Neurobiol Dis"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev-med-050715-104343","volume":"69","author":"Labzin L.I.","year":"2018","unstructured":"Labzin L.I.; Heneka M.T.; Latz E.; Innate immunity and neurodegeneration. Annu Rev Med  2018,69(1),437-449","journal-title":"Annu Rev Med"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cns.13569","volume":"27","author":"Huang X.","year":"2021","unstructured":"Huang X.; Hussain B.; Chang J.; Peripheral inflammation and blood\u2013brain barrier disruption: Effects and mechanisms. CNS Neurosci Ther  2021,27(1),36-47","journal-title":"CNS Neurosci Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e1143544","DOI":"10.1080\/21688370.2016.1143544","volume":"4","author":"Wilhelm I.","year":"2016","unstructured":"Wilhelm I.; Ny\u00fal-T\u00f3th \u00c1.; Suciu M.; Hermenean A.; Krizbai I.A.; Heterogeneity of the blood-brain barrier. Tissue Barriers  2016,4(1),e1143544","journal-title":"Tissue Barriers"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"572090","DOI":"10.3389\/fnagi.2020.572090","volume":"12","author":"Mayne K.","year":"2020","unstructured":"Mayne K.; White J.A.; McMurran C.E.; Rivera F.J.; de la Fuente A.G.; Aging and neurodegenerative disease: Is the adaptive immune system a friend or foe? Front Aging Neurosci  2020,12,572090","journal-title":"Front Aging Neurosci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","volume":"140","author":"Glass C.K.","year":"2010","unstructured":"Glass C.K.; Saijo K.; Winner B.; Marchetto M.C.; Gage F.H.; Mechanisms underlying inflammation in neurodegeneration. Cell  2010,140(6),918-934","journal-title":"Cell"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/imm.12922","volume":"154","author":"Stephenson J.","year":"2018","unstructured":"Stephenson J.; Nutma E.; van der Valk P.; Amor S.; Inflammation in CNS neurodegenerative diseases. Immunology  2018,154(2),204-219","journal-title":"Immunology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"855776","DOI":"10.3389\/fnagi.2022.855776","volume":"14","author":"Fathi M.","year":"2022","unstructured":"Fathi M.; Vakili K.; Yaghoobpoor S.; Qadirifard M.S.; Kosari M.; Naghsh N.;; Asgari taei, A.; Klegeris, A.; Dehghani, M.; Bahrami, A.; Taheri, H.; Mohamadkhani, A.; Hajibeygi, R.; Rezaei Tavirani, M.; Sayehmiri, F. Pre-clinical studies identifying molecular pathways of neuroinflammation in Parkinson\u2019s disease: A systematic review. Front Aging Neurosci  2022,14,855776","journal-title":"Front Aging Neurosci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40035-021-00271-0","volume":"10","author":"Gorecki A.M.","year":"2021","unstructured":"Gorecki A.M.; Anyaegbu C.C.; Anderton R.S.; TLR2 and TLR4 in Parkinson\u2019s disease pathogenesis: The environment takes a toll on the gut. Transl Neurodegener  2021,10(1),47","journal-title":"Transl Neurodegener"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3389\/fnagi.2020.00068","volume":"12","author":"Bellucci A.","year":"2020","unstructured":"Bellucci A.; Bubacco L.; Longhena F.; Parrella E.; Faustini G.; Porrini V.; Bono F.; Missale C.; Pizzi M.; Nuclear Factor-\u03baB dysregulation and \u03b1-synuclein pathology: Critical interplay in the pathogenesis of Parkinson\u2019s disease. Front Aging Neurosci  2020,12,68","journal-title":"Front Aging Neurosci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s12264-022-00878-x","volume":"38","author":"Juranek J.","year":"2022","unstructured":"Juranek J.; Mukherjee K.; Kordas B.;; Za\u0142\u0119cki, M.; Korytko, A.; Zglejc-Waszak, K.; Szuszkiewicz, J.; Banach, M. Role of RAGE in the pathogenesis of neurological disorders. Neurosci Bull  2022,38(10),1248-1262","journal-title":"Neurosci Bull"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.bbi.2009.02.015","volume":"23","author":"Spulber S.","year":"2009","unstructured":"Spulber S.; Bartfai T.; Schultzberg M.; IL-1\/IL-1ra balance in the brain revisited: Evidence from transgenic mouse models. Brain Behav Immun  2009,23(5),573-579","journal-title":"Brain Behav Immun"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"701282","DOI":"10.3389\/fimmu.2021.701282","volume":"12","author":"Bai H.","year":"2021","unstructured":"Bai H.; Zhang Q.; Activation of NLRP3 inflammasome and onset of Alzheimer\u2019s disease. Front Immunol  2021,12,701282","journal-title":"Front Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3233\/JPD-191724","volume":"10","author":"Martin-Ruiz C.","year":"2020","unstructured":"Martin-Ruiz C.; Williams-Gray C.H.; Yarnall A.J.; Boucher J.J.; Lawson R.A.; Wijeyekoon R.S.; Barker R.A.; Kolenda C.; Parker C.; Burn D.J.; Von Zglinicki T.; Saretzki G.; Senescence and inflammatory markers for predicting clinical progression in Parkinson\u2019s disease: The ICICLE-PD Study. J Parkinsons Dis  2020,10(1),193-206","journal-title":"J Parkinsons Dis"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"756","DOI":"10.14336\/AD.2020.0601","volume":"11","author":"Lara P.C.","year":"2020","unstructured":"Lara P.C.; Mac\u00edas-Verde D.; Burgos-Burgos J.; Age-induced NLRP3 inflammasome over-activation increases lethality of SARS-CoV-2 pneumonia in elderly patients. Aging Dis  2020,11(4),756-762","journal-title":"Aging Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.4049\/jimmunol.1103051","volume":"188","author":"Stout-Delgado H.W.","year":"2012","unstructured":"Stout-Delgado H.W.; Vaughan S.E.; Shirali A.C.; Jaramillo R.J.; Harrod K.S.; Impaired NLRP3 inflammasome function in elderly mice during influenza infection is rescued by treatment with nigericin. J Immunol  2012,188(6),2815-2824","journal-title":"J Immunol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-3-7091-6301-6_19","author":"Nagatsu T.","year":"2000","unstructured":"Nagatsu T.; Mogi M.; Ichinose H.; Togari A.; Changes in cytokines and neurotrophins in Parkinson\u2019s disease. J Neural Transm Suppl  2000(60),277-290","journal-title":"J Neural Transm Suppl"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/mds.26488","volume":"31","author":"Zhang P.","year":"2016","unstructured":"Zhang P.; Shao X.Y.; Qi G.J.; Chen Q.; Bu L.L.; Chen L.J.; Shi J.; Ming J.; Tian B.; Cdk5-dependent activation of neuronal inflammasomes in Parkinson\u2019s disease. Mov Disord  2016,31(3),366-376","journal-title":"Mov Disord"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"6539","DOI":"10.4049\/jimmunol.1100620","volume":"187","author":"Kitazawa M.","year":"2011","unstructured":"Kitazawa M.; Cheng D.; Tsukamoto M.R.; Koike M.A.; Wes P.D.; Vasilevko V.; Cribbs D.H.; LaFerla F.M.; Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal \u03b2-catenin pathway function in an Alzheimer\u2019s disease model. J Immunol  2011,187(12),6539-6549","journal-title":"J Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.1073\/pnas.1610099113","volume":"113","author":"Wang W.","year":"2016","unstructured":"Wang W.; Nguyen L.T.T.; Burlak C.; Chegini F.; Guo F.; Chataway T.; Ju S.; Fisher O.S.; Miller D.W.; Datta D.; Wu F.; Wu C.X.; Landeru A.; Wells J.A.; Cookson M.R.; Boxer M.B.; Thomas C.J.; Gai W.P.; Ringe D.; Petsko G.A.; Hoang Q.Q.; Caspase-1 causes truncation and aggregation of the Parkinson\u2019s disease-associated protein \u03b1-synuclein. Proc Natl Acad Sci  2016,113(34),9587-9592","journal-title":"Proc Natl Acad Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1006\/exnr.2001.7749","volume":"171","author":"Hurelbrink C.B.","year":"2001","unstructured":"Hurelbrink C.B.; Armstrong R.J.E.; Luheshi L.M.; Dunnett S.B.; Rosser A.E.; Barker R.A.; Death of dopaminergic neurons in vitro and in nigral grafts: Reevaluating the role of caspase activation. Exp Neurol  2001,171(1),46-58","journal-title":"Exp Neurol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.3390\/ijms19061689","volume":"19","author":"Caputi V.","year":"2018","unstructured":"Caputi V.; Giron M.; Microbiome-gut-brain axis and toll-like receptors in Parkinson\u2019s disease. Int J Mol Sci  2018,19(6),1689","journal-title":"Int J Mol Sci"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1007\/s12035-022-02756-z","volume":"59","author":"Howe A.M.","year":"2022","unstructured":"Howe A.M.; Burke S.; O\u2019Reilly M.E.; McGillicuddy F.C.; Costello D.A.; Palmitic acid and oleic acid differently modulate tlr2-mediated inflammatory responses in microglia and macrophages. Mol Neurobiol  2022,59(4),2348-2362","journal-title":"Mol Neurobiol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.neulet.2005.08.047","volume":"391","author":"Minoretti P.","year":"2006","unstructured":"Minoretti P.; Gazzaruso C.; Vito C.D.; Emanuele E.; Bianchi M.; Coen E.; Reino M.; Geroldi D.; Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer\u2019s disease. Neurosci Lett  2006,391(3),147-149","journal-title":"Neurosci Lett"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.brainresrev.2008.09.001","volume":"59","author":"Okun E.","year":"2009","unstructured":"Okun E.; Griffioen K.J.; Lathia J.D.; Tang S.C.; Mattson M.P.; Arumugam T.V.; Toll-like receptors in neurodegeneration. Brain Res Brain Res Rev  2009,59(2),278-292","journal-title":"Brain Res Brain Res Rev"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","volume":"46","author":"Liddelow S.A.","year":"2017","unstructured":"Liddelow S.A.; Barres B.A.; Reactive Astrocytes: Production, Function, and Therapeutic Potential. Immunity  2017,46(6),957-967","journal-title":"Immunity"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"870085","DOI":"10.3389\/fnmol.2022.870085","volume":"15","author":"Labib D.","year":"2022","unstructured":"Labib D.; Wang Z.; Prakash P.; Zimmer M.; Smith M.D.; Frazel P.W.; Barbar L.; Sapar M.L.; Calabresi P.A.; Peng J.; Liddelow S.A.; Fossati V.; Proteomic Alterations and Novel Markers of Neurotoxic Reactive Astrocytes in Human Induced Pluripotent Stem Cell Models. Front Mol Neurosci  2022,15,870085","journal-title":"Front Mol Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12035-013-8595-3","volume":"50","author":"Zhao Y.","year":"2014","unstructured":"Zhao Y.; Bhattacharjee S.; Jones B.M.; Hill J.; Dua P.; Lukiw W.J.; Regulation of neurotropic signaling by the inducible, NF-kB-sensitive miRNA-125b in Alzheimer\u2019s disease (AD) and in primary human neuronal-glial (HNG) cells. Mol Neurobiol  2014,50(1),97-106","journal-title":"Mol Neurobiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2174\/1570159X18666200207120949","volume":"18","author":"Singh S.","year":"2020","unstructured":"Singh S.; Singh T.G.; Role of Nuclear Factor Kappa B (NF-\u03baB) signalling in neurodegenerative diseases: A mechanistic approach. Curr Neuropharmacol  2020,18(10),918-935","journal-title":"Curr Neuropharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13041-018-0418-z","volume":"11","author":"Dou F.","year":"2018","unstructured":"Dou F.; Chu X.; Zhang B.; Liang L.; Lu G.; Ding J.; Chen S.; EriB targeted inhibition of microglia activity attenuates MPP+ induced DA neuron injury through the NF-\u03baB signaling pathway. Mol Brain  2018,11(1),75","journal-title":"Mol Brain"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.3390\/molecules27103194","volume":"27","author":"Rauf A.","year":"2022","unstructured":"Rauf A.; Badoni H.; Abu-Izneid T.; Olatunde A.; Rahman M.M.; Painuli S.; Semwal P.; Wilairatana P.; Mubarak M.S.; Neuroinflammatory markers: Key indicators in the pathology of neurodegenerative diseases. Molecules  2022,27(10),3194","journal-title":"Molecules"},{"key":"ref=53","first-page":"113","volume":"2","author":"Huang Y.","year":"2005","unstructured":"Huang Y.; Erdmann N.; Peng H.; Zhao Y.; Zheng J.; The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell Mol Immunol  2005,2(2),113-122","journal-title":"Cell Mol Immunol"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00001756-200403220-00002","volume":"15","author":"Uberti D.","year":"2004","unstructured":"Uberti D.; Cantarella G.; Facchetti F.; Cafici A.; Grasso G.; Bernardini R.; Memo M.; TRAIL is expressed in the brain cells of Alzheimer\u2019s disease patients. Neuroreport  2004,15(4),579-581","journal-title":"Neuroreport"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","volume":"21","author":"Akiyama H.","year":"2000","unstructured":"Akiyama H.; Barger S.; Barnum S.; Bradt B.; Bauer J.; Cole G.M.; Cooper N.R.; Eikelenboom P.; Emmerling M.; Fiebich B.L.; Finch C.E.; Frautschy S.; Griffin W.S.; Hampel H.; Hull M.; Landreth G.; Lue L.; Mrak R.; Mackenzie I.R.; McGeer P.L.; O\u2019Banion M.K.; Pachter J.; Pasinetti G.; Plata-Salaman C.; Rogers J.; Rydel R.; Shen Y.; Streit W.; Strohmeyer R.; Tooyoma I.; Van Muiswinkel F.L.; Veerhuis R.; Walker D.; Webster S.; Wegrzyniak B.; Wenk G.; Wyss-Coray T.; Inflammation and Alzheimer\u2019s disease. Neurobiol Aging  2000,21(3),383-421","journal-title":"Neurobiol Aging"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1159\/000051276","volume":"12","author":"Tarkowski E.","year":"2001","unstructured":"Tarkowski E.; Liljeroth A.M.; Nilsson \u00c5.; Minthon L.; Blennow K.; Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer\u2019s disease. Dement Geriatr Cogn Disord  2001,12(5),314-317","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1083\/jcb.200705042","volume":"178","author":"He P.","year":"2007","unstructured":"He P.; Zhong Z.; Lindholm K.; Berning L.; Lee W.; Lemere C.; Staufenbiel M.; Li R.; Shen Y.; Deletion of tumor necrosis factor death receptor inhibits amyloid \u03b2 generation and prevents learning and memory deficits in Alzheimer\u2019s mice. J Cell Biol  2007,178(5),829-841","journal-title":"J Cell Biol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"8354","DOI":"10.1523\/JNEUROSCI.0616-08.2008","volume":"28","author":"Hickman S.E.","year":"2008","unstructured":"Hickman S.E.; Allison E.K.; El Khoury J.; Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer\u2019s disease mice. J Neurosci  2008,28(33),8354-8360","journal-title":"J Neurosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/cells9030600","volume":"9","author":"Nutma E.","year":"2020","unstructured":"Nutma E.; van Gent D.; Amor S.; Peferoen L.A.N.; Astrocyte and oligodendrocyte cross-talk in the central nervous system. Cells  2020,9(3),600","journal-title":"Cells"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/JLB.3MR0118-003R","volume":"103","author":"Santoro A.","year":"2018","unstructured":"Santoro A.; Spinelli C.C.; Martucciello S.; Nori S.L.; Capunzo M.; Puca A.A.; Ciaglia E.; Innate immunity and cellular senescence: The good and the bad in the developmental and aged brain. J Leukoc Biol  2018,103(3),509-524","journal-title":"J Leukoc Biol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1212\/01.wnl.0000263217.36439.da","volume":"68","author":"Tan Z.S.","year":"2007","unstructured":"Tan Z.S.; Beiser A.S.; Vasan R.S.; Roubenoff R.; Dinarello C.A.; Harris T.B.; Benjamin E.J.; Au R.; Kiel D.P.; Wolf P.A.; Seshadri S.; Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology  2007,68(22),1902-1908","journal-title":"Neurology"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"a024091","DOI":"10.1101\/cshperspect.a024091","volume":"8","author":"Burr\u00e9 J.","year":"2018","unstructured":"Burr\u00e9 J.; Sharma M.; S\u00fcdhof T.C.; Cell biology and pathophysiology of \u03b1-synuclein. Cold Spring Harb Perspect Med  2018,8(3),a024091","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/1673-5374.264444","volume":"15","author":"Nakanishi H.","year":"2020","unstructured":"Nakanishi H.; Microglial cathepsin B as a key driver of inflammatory brain diseases and brain aging. Neural Regen Res  2020,15(1),25-29","journal-title":"Neural Regen Res"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/ncomms2534","volume":"4","author":"Kim C.","year":"2013","unstructured":"Kim C.; Ho D.H.; Suk J.E.; You S.; Michael S.; Kang J.; Joong Lee S.; Masliah E.; Hwang D.; Lee H.J.; Lee S.J.; Neuron-released oligomeric \u03b1-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun  2013,4(1),1562","journal-title":"Nat Commun"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"4918","DOI":"10.1038\/s41467-022-32625-1","volume":"13","author":"Xie Y.X.","year":"2022","unstructured":"Xie Y.X.; Naseri N.N.; Fels J.; Kharel P.; Na Y.; Lane D.; Burr\u00e9 J.; Sharma M.; Lysosomal exocytosis releases pathogenic \u03b1-synuclein species from neurons in synucleinopathy models. Nat Commun  2022,13(1),4918","journal-title":"Nat Commun"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","volume":"14","author":"Lashuel H.A.","year":"2013","unstructured":"Lashuel H.A.; Overk C.R.; Oueslati A.; Masliah E.; The many faces of \u03b1-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci  2013,14(1),38-48","journal-title":"Nat Rev Neurosci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","volume":"79","author":"Bendor J.T.","year":"2013","unstructured":"Bendor J.T.; Logan T.P.; Edwards R.H.; The function of \u03b1-synuclein. Neuron  2013,79(6),1044-1066","journal-title":"Neuron"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1007\/s00415-022-11491-3","volume":"270","author":"Soraci L.","year":"2023","unstructured":"Soraci L.; Gambuzza M.E.; Biscetti L.; Lagan\u00e0 P.; Lo Russo C.; Buda A.; Barresi G.; Corsonello A.; Lattanzio F.; Lorello G.; Filippelli G.; Marino S.; Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson\u2019s disease: Mechanisms and therapeutic implications. J Neurol  2023,270(3),1346-1360","journal-title":"J Neurol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/B978-0-444-63945-5.00017-9","volume":"153","author":"Volpicelli-Daley L.","year":"2018","unstructured":"Volpicelli-Daley L.; Brundin P.; Prion-like propagation of pathology in Parkinson disease. Handb Clin Neurol  2018,153,321-335","journal-title":"Handb Clin Neurol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"10215","DOI":"10.3390\/ijms241210215","volume":"24","author":"Noguchi-Shinohara M.","year":"2023","unstructured":"Noguchi-Shinohara M.; Ono K.; The mechanisms of the roles of \u03b1-synuclein, amyloid-\u03b2, and tau protein in the lewy body diseases: pathogenesis, early detection, and therapeutics. Int J Mol Sci  2023,24(12),10215","journal-title":"Int J Mol Sci"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00415-004-0483-3","volume":"251","author":"Schrag A.","year":"2004","unstructured":"Schrag A.; Psychiatric aspects of Parkinson\u2019s disease. J Neurol  2004,251(7),795-804","journal-title":"J Neurol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1094351","DOI":"10.3389\/fphar.2022.1094351","volume":"13","author":"Subramanian A.","year":"2022","unstructured":"Subramanian A.; Tamilanban T.; Alsayari A.; Ramachawolran G.; Wong L.S.; Sekar M.; Gan S.H.; Subramaniyan V.; Chinni S.V.; Izzati Mat Rani N.N.; Suryadevara N.; Wahab S.; Trilateral association of autophagy, mTOR and Alzheimer\u2019s disease: Potential pathway in the development for Alzheimer\u2019s disease therapy. Front Pharmacol  2022,13,1094351","journal-title":"Front Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.bbadva.2022.100066","volume":"2","author":"Kostiuchenko O.","year":"2022","unstructured":"Kostiuchenko O.; Lushnikova I.; Kowalczyk M.; Skibo G.; mTOR\/\u03b1-ketoglutarate-mediated signaling pathways in the context of brain neurodegeneration and neuroprotection. BBA Adv  2022,2,100066","journal-title":"BBA Adv"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"6954","DOI":"10.3390\/ijms23136954","volume":"23","author":"Blagov A.V.","year":"2022","unstructured":"Blagov A.V.; Grechko A.V.; Nikiforov N.G.; Borisov E.E.; Sadykhov N.K.; Orekhov A.N.; Role of impaired mitochondrial dynamics processes in the pathogenesis of Alzheimer\u2019s disease. Int J Mol Sci  2022,23(13),6954","journal-title":"Int J Mol Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.nbd.2018.11.004","volume":"124","author":"Ikeda-Matsuo Y.","year":"2019","unstructured":"Ikeda-Matsuo Y.; Miyata H.; Mizoguchi T.; Ohama E.; Naito Y.; Uematsu S.; Akira S.; Sasaki Y.; Tanabe M.; Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson\u2019s disease. Neurobiol Dis  2019,124,81-92","journal-title":"Neurobiol Dis"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s42255-023-00756-4","volume":"5","author":"Mi Y.","year":"2023","unstructured":"Mi Y.; Qi G.; Vitali F.; Shang Y.; Raikes A.C.; Wang T.; Jin Y.; Brinton R.D.; Gu H.; Yin F.; Loss of fatty acid degradation by astrocytic mitochondria triggers neuroinflammation and neurodegeneration. Nat Metab  2023,5(3),445-465","journal-title":"Nat Metab"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"9782","DOI":"10.18632\/aging.204384","volume":"14","author":"Kulminski A.M.","year":"2022","unstructured":"Kulminski A.M.; Jain-Washburn E.; Loiko E.; Loika Y.; Feng F.; Culminskaya I.; Associations of the APOE \u03b52 and \u03b54 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer\u2019s disease biomarkers. Aging  2022,14(24),9782-9804","journal-title":"Aging"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"109544","DOI":"10.1016\/j.intimp.2022.109544","volume":"114","author":"Mu G.","year":"2023","unstructured":"Mu G.; Ren C.; Zhang Y.; Lu B.; Feng J.; Wu D.; Xu X.; Ou C.; Amelioration of central neurodegeneration by docosahexaenoic acid in trigeminal neuralgia rats through the regulation of central neuroinflammation. Int Immunopharmacol  2023,114,109544","journal-title":"Int Immunopharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/mds.29128","volume":"37","author":"Xie A.","year":"2022","unstructured":"Xie A.; Ensink E.; Li P.;; Gordevi\u010dius, J.; Marshall, L.L.; George, S.; Pospisilik, J.A.; Aho, V.T.E.; Houser, M.C.; Pereira, P.A.B.; Rudi, K.; Paulin, L.; Tansey, M.G.; Auvinen, P.; Brundin, P.; Brundin, L.; Labrie, V.; Scheperjans, F. Bacterial butyrate in parkinson\u2019s disease is linked to epigenetic changes and depressive symptoms. Mov Disord  2022,37(8),1644-1653","journal-title":"Mov Disord"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"794519","DOI":"10.3389\/fimmu.2021.794519","volume":"12","author":"Verhaar B.J.H.","year":"2022","unstructured":"Verhaar B.J.H.; Hendriksen H.M.A.; de Leeuw F.A.; Doorduijn A.S.; van Leeuwenstijn M.; Teunissen C.E.; Barkhof F.; Scheltens P.; Kraaij R.; van Duijn C.M.; Nieuwdorp M.; Muller M.; van der Flier W.M.; Gut microbiota composition is related to ad pathology. Front Immunol  2022,12,794519","journal-title":"Front Immunol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1038\/s41598-023-31730-5","volume":"13","author":"Cammann D.","year":"2023","unstructured":"Cammann D.; Lu Y.; Cummings M.J.; Zhang M.L.; Cue J.M.; Do J.; Ebersole J.; Chen X.; Oh E.C.; Cummings J.L.; Chen J.; Genetic correlations between Alzheimer\u2019s disease and gut microbiome genera. Sci Rep  2023,13(1),5258","journal-title":"Sci Rep"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1549549","volume":"2018","author":"Lang Y.","year":"2018","unstructured":"Lang Y.; Chu F.; Shen D.; Zhang W.; Zheng C.; Zhu J.; Cui L.; Role of inflammasomes in neuroimmune and neurodegenerative diseases: A systematic review. Mediators Inflamm  2018,2018,1-11","journal-title":"Mediators Inflamm"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1201982","DOI":"10.3389\/fnagi.2023.1201982","volume":"15","author":"Miao J.","year":"2023","unstructured":"Miao J.; Ma H.; Yang Y.; Liao Y.; Lin C.; Zheng J.; Yu M.; Lan J.; Microglia in Alzheimer\u2019s disease: Pathogenesis, mechanisms, and therapeutic potentials. Front Aging Neurosci  2023,15,1201982","journal-title":"Front Aging Neurosci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/glia.22866","volume":"64","author":"Wes P.D.","year":"2016","unstructured":"Wes P.D.; Holtman I.R.; Boddeke E.W.G.M.; M\u00f6ller T.; Eggen B.J.L.; Next generation transcriptomics and genomics elucidate biological complexity of microglia in health and disease. Glia  2016,64(2),197-213","journal-title":"Glia"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40478-015-0203-5","volume":"3","author":"Holtman I.R.","year":"2015","unstructured":"Holtman I.R.; Raj D.D.; Miller J.A.; Schaafsma W.; Yin Z.; Brouwer N.; Wes P.D.; M\u00f6ller T.; Orre M.; Kamphuis W.; Hol E.M.; Boddeke E.W.G.M.; Eggen B.J.L.; Induction of a common microglia gene expression signature by aging and neurodegenerative conditions: A co-expression meta-analysis. Acta Neuropathol Commun  2015,3(1),31","journal-title":"Acta Neuropathol Commun"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12974-020-01774-9","volume":"17","author":"Pan J.","year":"2020","unstructured":"Pan J.; Ma N.; Yu B.; Zhang W.; Wan J.; Transcriptomic profiling of microglia and astrocytes throughout aging. J Neuroinflammation  2020,17(1),97","journal-title":"J Neuroinflammation"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"eabi8593","DOI":"10.1126\/scitranslmed.abi8593","volume":"14","author":"Spurrier J.","year":"2022","unstructured":"Spurrier J.; Nicholson L.; Fang X.T.; Stoner A.J.; Toyonaga T.; Holden D.; Siegert T.R.; Laird W.; Allnutt M.A.; Chiasseu M.; Brody A.H.; Takahashi H.; Nies S.H.; Ca\u00f1am\u00e1s A.P.; Sadasivam P.; Lee S.; Li S.; Zhang L.; Huang Y.H.; Carson R.E.; Cai Z.; Strittmatter S.M.; Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci Transl Med  2022,14(647),eabi8593","journal-title":"Sci Transl Med"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"102488","DOI":"10.1016\/j.pneurobio.2023.102488","volume":"228","author":"Balog B.M.","year":"2023","unstructured":"Balog B.M.; Sonti A.; Zigmond R.E.; Neutrophil biology in injuries and diseases of the central and peripheral nervous systems. Prog Neurobiol  2023,228,102488","journal-title":"Prog Neurobiol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1123149","DOI":"10.3389\/fimmu.2023.1123149","volume":"14","author":"Aries M.L.","year":"2023","unstructured":"Aries M.L.; Hensley-McBain T.; Neutrophils as a potential therapeutic target in Alzheimer\u2019s disease. Front Immunol  2023,14,1123149","journal-title":"Front Immunol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3390\/ijms22041924","volume":"22","author":"Harcha P.A.","year":"2021","unstructured":"Harcha P.A.; Garc\u00e9s P.; Arredondo C.; Fern\u00e1ndez G.; S\u00e1ez J.C.; van Zundert B.; Mast cell and astrocyte hemichannels and their role in alzheimer\u2019s disease, ALS, and harmful stress conditions. Int J Mol Sci  2021,22(4),1924","journal-title":"Int J Mol Sci"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"837250","DOI":"10.3389\/fimmu.2022.837250","volume":"13","author":"Wang S.","year":"2022","unstructured":"Wang S.; van de Pavert S.A.; Innate lymphoid cells in the central nervous system. Front Immunol  2022,13,837250","journal-title":"Front Immunol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/cells11061017","volume":"11","author":"Brauning A.","year":"2022","unstructured":"Brauning A.; Rae M.; Zhu G.; Fulton E.; Admasu T.D.; Stolzing A.; Sharma A.; Aging of the immune system: Focus on natural killer cells phenotype and functions. Cells  2022,11(6),1017","journal-title":"Cells"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/JLB.MR0718-269R","volume":"105","author":"Prager I.","year":"2019","unstructured":"Prager I.; Watzl C.; Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol  2019,105(6),1319-1329","journal-title":"J Leukoc Biol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.3233\/JPD-223212","volume":"12","author":"Menees K.B.","year":"2022","unstructured":"Menees K.B.; Lee J.K.; New insights and implications of natural killer cells in parkinson\u2019s disease. J Parkinsons Dis  2022,12(s1),S83-S92","journal-title":"J Parkinsons Dis"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"890816","DOI":"10.3389\/fnagi.2022.890816","volume":"14","author":"Zhang L.","year":"2022","unstructured":"Zhang L.; Zhang Y.; Fan D.; Pathological role of natural killer cells in parkinson\u2019s disease: A systematic review. Front Aging Neurosci  2022,14,890816","journal-title":"Front Aging Neurosci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13317-019-0124-6","volume":"11","author":"Mu\u00f1iz-Castrillo S.","year":"2020","unstructured":"Mu\u00f1iz-Castrillo S.; Vogrig A.; Honnorat J.; Associations between HLA and autoimmune neurological diseases with autoantibodies. Auto Immun Highlights  2020,11(1),2","journal-title":"Auto Immun Highlights"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12974-018-1180-y","volume":"15","author":"Boon B.D.C.","year":"2018","unstructured":"Boon B.D.C.; Hoozemans J.J.M.; Lopuha\u00e4 B.; Eigenhuis K.N.; Scheltens P.; Kamphorst W.; Rozemuller A.J.M.; Bouwman F.H.; Neuroinflammation is increased in the parietal cortex of atypical Alzheimer\u2019s disease. J Neuroinflammation  2018,15(1),170","journal-title":"J Neuroinflammation"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"4521","DOI":"10.18632\/aging.102066","volume":"11","author":"Wang Z.T.","year":"2019","unstructured":"Wang Z.T.; Chen S.D.; Xu W.; Chen K.L.; Wang H.F.; Tan C.C.; Cui M.; Dong Q.; Tan L.; Yu J.T.; Genome-wide association study identifies CD1A associated with rate of increase in plasma neurofilament light in non-demented elders. Aging  2019,11(13),4521-4535","journal-title":"Aging"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3389\/fphys.2020.00598","volume":"11","author":"Chew H.","year":"2020","unstructured":"Chew H.; Solomon V.A.; Fonteh A.N.; Involvement of lipids in Alzheimer\u2019s disease pathology and potential therapies. Front Physiol  2020,11,598","journal-title":"Front Physiol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"e01063","DOI":"10.1002\/prp2.1063","volume":"11","author":"Al-kuraishy H.M.","year":"2023","unstructured":"Al-kuraishy H.M.; Al-Gareeb A.I.; Alexiou A.; Papadakis M.; Alsayegh A.A.; Almohmadi N.H.; Saad H.M.; Batiha G.E.S.; Pros and cons for statins use and risk of Parkinson\u2019s disease: An updated perspective. Pharmacol Res Perspect  2023,11(2),e01063","journal-title":"Pharmacol Res Perspect"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nature22815","volume":"546","author":"Sulzer D.","year":"2017","unstructured":"Sulzer D.; Alcalay R.N.; Garretti F.; Cote L.; Kanter E.; Agin-Liebes J.; Liong C.; McMurtrey C.; Hildebrand W.H.; Mao X.; Dawson V.L.; Dawson T.M.; Oseroff C.; Pham J.; Sidney J.; Dillon M.B.; Carpenter C.; Weiskopf D.; Phillips E.; Mallal S.; Peters B.; Frazier A.; Lindestam A.C.S.; Sette A.; T cells from patients with Parkinson\u2019s disease recognize \u03b1-synuclein peptides. Nature  2017,546(7660),656-661","journal-title":"Nature"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/brain\/awab103","volume":"144","author":"Williams G.P.","year":"2021","unstructured":"Williams G.P.; Schonhoff A.M.; Jurkuvenaite A.; Gallups N.J.; Standaert D.G.; Harms A.S.; CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson\u2019s disease. Brain  2021,144(7),2047-2059","journal-title":"Brain"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12974-020-01888-0","volume":"17","author":"Iba M.","year":"2020","unstructured":"Iba M.; Kim C.; Sallin M.; Kwon S.; Verma A.; Overk C.; Rissman R.A.; Sen R.; Sen J.M.; Masliah E.; Neuroinflammation is associated with infiltration of T cells in Lewy body disease and \u03b1-synuclein transgenic models. J Neuroinflammation  2020,17(1),214","journal-title":"J Neuroinflammation"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neures.2013.10.004","volume":"79","author":"Lyman M.","year":"2014","unstructured":"Lyman M.; Lloyd D.G.; Ji X.; Vizcaychipi M.P.; Ma D.; Neuroinflammation: The role and consequences. Neurosci Res  2014,79,1-12","journal-title":"Neurosci Res"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41577-021-00557-4","volume":"22","author":"Carrasco E.","year":"2022","unstructured":"Carrasco E.; G\u00f3mez de las Heras M.M.; Gaband\u00e9-Rodr\u00edguez E.; Desd\u00edn-Mic\u00f3 G.; Aranda J.F.; Mittelbrunn M.; The role of T cells in age-related diseases. Nat Rev Immunol  2022,22(2),97-111","journal-title":"Nat Rev Immunol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","volume":"577","author":"Gate D.","year":"2020","unstructured":"Gate D.; Saligrama N.; Leventhal O.; Yang A.C.; Unger M.S.; Middeldorp J.; Chen K.; Lehallier B.; Channappa D.; De Los Santos M.B.; McBride A.; Pluvinage J.; Elahi F.; Tam G.K.Y.; Kim Y.; Greicius M.; Wagner A.D.; Aigner L.; Galasko D.R.; Davis M.M.; Wyss-Coray T.; Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease. Nature  2020,577(7790),399-404","journal-title":"Nature"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/4626540","volume":"2017","author":"Mietelska-Porowska A.","year":"2017","unstructured":"Mietelska-Porowska A.; Wojda U.; T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer\u2019s disease: Potential pools of new biomarkers. J Immunol Res  2017,2017,1-17","journal-title":"J Immunol Res"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s11481-009-9166-2","volume":"4","author":"Rezai-Zadeh K.","year":"2009","unstructured":"Rezai-Zadeh K.; Gate D.; Town T.; CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol  2009,4(4),462-475","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"e13511","DOI":"10.1111\/acel.13511","volume":"20","author":"Dai L.","year":"2021","unstructured":"Dai L.; Shen Y.; Insights into Tcell dysfunction in Alzheimer\u2019s disease. Aging Cell  2021,20(12),e13511","journal-title":"Aging Cell"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12974-021-02308-7","volume":"18","author":"Machhi J.","year":"2021","unstructured":"Machhi J.; Yeapuri P.; Lu Y.; Foster E.; Chikhale R.; Herskovitz J.; Namminga K.L.; Olson K.E.; Abdelmoaty M.M.; Gao J.; Quadros R.M.; Kiyota T.; Jingjing L.; Kevadiya B.D.; Wang X.; Liu Y.; Poluektova L.Y.; Gurumurthy C.B.; Mosley R.L.; Gendelman H.E.; CD4+ effector T cells accelerate Alzheimer\u2019s disease in mice. J Neuroinflammation  2021,18(1),272","journal-title":"J Neuroinflammation"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1172\/JCI200318104","volume":"112","author":"Monsonego A.","year":"2003","unstructured":"Monsonego A.; Zota V.; Karni A.; Krieger J.I.; Bar-Or A.; Bitan G.; Budson A.E.; Sperling R.; Selkoe D.J.; Weiner H.L.; Increased T cell reactivity to amyloid \u03b2 protein in older humans and patients with Alzheimer disease. J Clin Invest  2003,112(3),415-422","journal-title":"J Clin Invest"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12974-018-1248-8","volume":"15","author":"Kustrimovic N.","year":"2018","unstructured":"Kustrimovic N.; Comi C.; Magistrelli L.; Rasini E.; Legnaro M.; Bombelli R.; Aleksic I.; Blandini F.; Minafra B.; Riboldazzi G.; Sturchio A.; Mauri M.; Bono G.; Marino F.; Cosentino M.; Parkinson\u2019s disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1\/Th2\/T17 and Treg in drug-na\u00efve and drug-treated patients. J Neuroinflammation  2018,15(1),205","journal-title":"J Neuroinflammation"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s11481-012-9402-z","volume":"7","author":"Saunders J.A.H.","year":"2012","unstructured":"Saunders J.A.H.; Estes K.A.; Kosloski L.M.; Allen H.E.; Dempsey K.M.; Torres-Russotto D.R.; Meza J.L.; Santamaria P.M.; Bertoni J.M.; Murman D.L.; Ali H.H.; Standaert D.G.; Mosley R.L.; Gendelman H.E.; CD4+ regulatory and effector\/memory T cell subsets profile motor dysfunction in Parkinson\u2019s disease. J Neuroimmune Pharmacol  2012,7(4),927-938","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12974-023-02723-y","volume":"20","author":"Xu Y.","year":"2023","unstructured":"Xu Y.; Li Y.; Wang C.; Han T.; Liu H.; Sun L.; Hong J.; Hashimoto M.; Wei J.; The reciprocal interactions between microglia and T cells in Parkinson\u2019s disease: A double-edged sword. J Neuroinflammation  2023,20(1),33","journal-title":"J Neuroinflammation"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"796","DOI":"10.4103\/1673-5374.295340","volume":"16","author":"Vacinova G.","year":"2021","unstructured":"Vacinova G.; Vejra\u017ekova D.; Rusina R.; Holmerov\u00e1 I.;; Va\u0148kov\u00e1, H.; Jarol\u00edmov\u00e1, E.; V\u010del\u00e1k, J.; Bendlov\u00e1, B.; Va\u0148kov\u00e1, M. Regulated upon activation, normal T cell expressed and secreted (RANTES) levels in the peripheral blood of patients with Alzheimer\u2019s disease. Neural Regen Res  2021,16(4),796-800","journal-title":"Neural Regen Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaut.2014.08.002","volume":"54","author":"Schwartz M.","year":"2014","unstructured":"Schwartz M.; Baruch K.; Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: Boosting autoimmunity to fight-off chronic neuroinflammation. J Autoimmun  2014,54,8-14","journal-title":"J Autoimmun"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41586-023-05788-0","volume":"615","author":"Chen X.","year":"2023","unstructured":"Chen X.; Firulyova M.; Manis M.; Herz J.; Smirnov I.; Aladyeva E.; Wang C.; Bao X.; Finn M.B.; Hu H.; Shchukina I.; Kim M.W.; Yuede C.M.; Kipnis J.; Artyomov M.N.; Ulrich J.D.; Holtzman D.M.; Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy. Nature  2023,615(7953),668-677","journal-title":"Nature"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12974-020-01911-4","volume":"17","author":"Subbarayan M.S.","year":"2020","unstructured":"Subbarayan M.S.; Hudson C.; Moss L.D.; Nash K.R.; Bickford P.C.; T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an \u03b1-synuclein rat model of Parkinson\u2019s disease. J Neuroinflammation  2020,17(1),242","journal-title":"J Neuroinflammation"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41531-021-00233-3","volume":"7","author":"Cai H.Y.","year":"2021","unstructured":"Cai H.Y.; Fu X.X.; Jiang H.; Han S.; Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinson\u2019s disease. NPJ Parkinsons Dis  2021,7(1),91","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"14600","DOI":"10.1038\/s41598-018-32712-8","volume":"8","author":"Liu Y.","year":"2018","unstructured":"Liu Y.; Sorce S.; Nuvolone M.; Domange J.; Aguzzi A.; Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression. Sci Rep  2018,8(1),14600","journal-title":"Sci Rep"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12974-019-1654-6","volume":"16","author":"Guo W.","year":"2019","unstructured":"Guo W.; Zhou M.; Qiu J.; Lin Y.; Chen X.; Huang S.; Mo M.; Liu H.; Peng G.; Zhu X.; Xu P.; Association of LAG3 genetic variation with an increased risk of PD in Chinese female population. J Neuroinflammation  2019,16(1),270","journal-title":"J Neuroinflammation"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"e13847","DOI":"10.1111\/eci.13847","volume":"52","author":"Garc\u00eda-Mart\u00edn E.","year":"2022","unstructured":"Garc\u00eda-Mart\u00edn E.; Pastor P.; G\u00f3mez-Tabales J.; Alonso-Navarro H.; Alvarez I.; Buongiorno M.; Cerezo-Arias M.O.; Aguilar M.; Ag\u00fandez J.A.G.; Jim\u00e9nez-Jim\u00e9nez F.J.; Association between LAG3\/CD4 gene variants and risk of Parkinson\u2019s disease. Eur J Clin Invest  2022,52(11),e13847","journal-title":"Eur J Clin Invest"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/mds.27569","volume":"34","author":"Cui S.","year":"2019","unstructured":"Cui S.; Du J.J.; Liu S.H.; Meng J.; Lin Y.Q.; Li G.; He Y.X.; Zhang P.C.; Chen S.; Wang G.; Serum soluble lymphocyte activation gene3 as a diagnostic biomarker in Parkinson\u2019s disease: A pilot multicenter study. Mov Disord  2019,34(1),138-141","journal-title":"Mov Disord"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.parkreldis.2021.09.019","volume":"91","author":"Roy A.","year":"2021","unstructured":"Roy A.; Choudhury S.; Banerjee R.; Basu P.; Kumar H.; Soluble LAG-3 and Toll-interacting protein: Novel upstream neuro-inflammatory markers in Parkinson\u2019s disease. Parkinsonism Relat Disord  2021,91,121-123","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3233\/JAD-2010-091696","volume":"21","author":"Saresella M.","year":"2010","unstructured":"Saresella M.; Calabrese E.; Marventano I.; Piancone F.; Gatti A.; Calvo M.G.; Nemni R.; Clerici M.; PD1 negative and PD1 positive CD4+ T regulatory cells in mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis  2010,21(3),927-938","journal-title":"J Alzheimers Dis"},{"key":"ref=126","first-page":"uxac084","author":"Olson K.E.","year":"2022","unstructured":"Olson K.E.; Mosley R.L.; Gendelman H.E.; The potential for treg-enhancing therapies in nervous system pathologies. Clin Exp Immunol  2022,uxac084","journal-title":"Clin Exp Immunol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"e89530","DOI":"10.1172\/jci.insight.89530","volume":"2","author":"Beers D.R.","year":"2017","unstructured":"Beers D.R.; Zhao W.; Wang J.; Zhang X.; Wen S.; Neal D.; Thonhoff J.R.; Alsuliman A.S.; Shpall E.J.; Rezvani K.; Appel S.H.; ALS patients\u2019 regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight  2017,2(5),e89530","journal-title":"JCI Insight"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.3389\/fneur.2018.01081","volume":"9","author":"Schr\u00f6der J.B.","year":"2018","unstructured":"Schr\u00f6der J.B.; Pawlowski M.; Meyer zu H\u00f6rste G.; Gross C.C.; Wiendl H.; Meuth S.G.; Ruck T.; Warnecke T.; Immune cell activation in the cerebrospinal fluid of patients with Parkinson\u2019s disease. Front Neurol  2018,9,1081","journal-title":"Front Neurol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12974-023-02702-3","volume":"20","author":"Stym-Popper G.","year":"2023","unstructured":"Stym-Popper G.; Matta K.; Chaigneau T.; Rupra R.; Demetriou A.; Fouquet S.; Dansokho C.; Toly-Ndour C.; Doroth\u00e9e G.; Regulatory T cells decrease C3-positive reactive astrocytes in Alzheimer-like pathology. J Neuroinflammation  2023,20(1),64","journal-title":"J Neuroinflammation"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"8788","DOI":"10.1038\/s41598-019-45433-3","volume":"9","author":"Ciccocioppo F.","year":"2019","unstructured":"Ciccocioppo F.; Lanuti P.; Pierdomenico L.; Simeone P.; Bologna G.; Ercolino E.; Buttari F.; Fantozzi R.; Thomas A.; Onofrj M.; Centonze D.; Miscia S.; Marchisio M.; The characterization of regulatory t-cell profiles in Alzheimer\u2019s disease and multiple sclerosis. Sci Rep  2019,9(1),8788","journal-title":"Sci Rep"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"7967","DOI":"10.1038\/ncomms8967","volume":"6","author":"Baruch K.","year":"2015","unstructured":"Baruch K.; Rosenzweig N.; Kertser A.; Deczkowska A.; Sharif A.M.; Spinrad A.; Tsitsou-Kampeli A.; Sarel A.; Cahalon L.; Schwartz M.; Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer\u2019s disease pathology. Nat Commun  2015,6(1),7967","journal-title":"Nat Commun"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1039239","DOI":"10.3389\/fpsyt.2023.1039239","volume":"14","author":"Novakova Martinkova J.","year":"2023","unstructured":"Novakova Martinkova J.; Ferretti M.T.; Ferrari A.; Lerch O.; Matuskova V.; Secnik J.; Hort J.; Longitudinal progression of choroid plexus enlargement is associated with female sex, cognitive decline and ApoE E4 homozygote status. Front Psychiatry  2023,14,1039239","journal-title":"Front Psychiatry"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"7668","DOI":"10.7150\/thno.75965","volume":"12","author":"Yang H.","year":"2022","unstructured":"Yang H.; Park S.Y.; Baek H.; Lee C.; Chung G.; Liu X.; Lee J.H.; Kim B.; Kwon M.; Choi H.; Kim H.J.; Kim J.Y.; Kim Y.; Lee Y.S.; Lee G.; Kim S.K.; Kim J.S.; Chang Y.T.; Jung W.S.; Kim K.H.; Bae H.; Adoptive therapy with amyloid-\u03b2 specific regulatory T cells alleviates Alzheimer\u2019s disease. Theranostics  2022,12(18),7668-7680","journal-title":"Theranostics"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jneuroim.2018.09.008","volume":"324","author":"Moore J.R.","year":"2018","unstructured":"Moore J.R.; Hubler S.L.; Nelson C.D.; Nashold F.E.; Spanier J.A.; Hayes C.E.; 1,25-Dihydroxyvitamin D3 increases the methionine cycle, CD4+ T cell DNA methylation and Helios+Foxp3+ T regulatory cells to reverse autoimmune neurodegenerative disease. J Neuroimmunol  2018,324,100-114","journal-title":"J Neuroimmunol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"120193","DOI":"10.1016\/j.lfs.2021.120193","volume":"289","author":"Janjusevic M.","year":"2022","unstructured":"Janjusevic M.; Gagno G.; Fluca A.L.; Padoan L.; Beltrami A.P.; Sinagra G.; Moretti R.; Aleksova A.; The peculiar role of vitamin D in the pathophysiology of cardiovascular and neurodegenerative diseases. Life Sci  2022,289,120193","journal-title":"Life Sci"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"932152","DOI":"10.3389\/fimmu.2022.932152","volume":"13","author":"Shi Y.","year":"2022","unstructured":"Shi Y.; Wei B.; Li L.; Wang B.; Sun M.; Th17 cells and inflammation in neurological disorders: Possible mechanisms of action. Front Immunol  2022,13,932152","journal-title":"Front Immunol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.stem.2019.04.019","volume":"24","author":"Sommer A.","year":"2019","unstructured":"Sommer A.; Marxreiter F.; Krach F.; Fadler T.; Grosch J.; Maroni M.; Graef D.; Eberhardt E.; Riemenschneider M.J.; Yeo G.W.; Kohl Z.; Xiang W.; Gage F.H.; Winkler J.; Prots I.; Winner B.; Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson\u2019s disease. Cell Stem Cell  2019,24(6),1006","journal-title":"Cell Stem Cell"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbi.2022.10.023","volume":"108","author":"Li J.","year":"2023","unstructured":"Li J.; Zhao, J.; Chen, L.; Gao, H.; Zhang, J.; Wang, D.; Zou, Y.; Qin, Q.; Qu, Y.; Li, J.; Xiong, Y.; Min, Z.; Yan, M.; Mao, Z.; Xue, Z. \u03b1-Synuclein induces Th17 differentiation and impairs the function and stability of Tregs by promoting RORC transcription in Parkinson\u2019s disease. Brain Behav Immun  2023,108,32-44","journal-title":"Brain Behav Immun"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1080\/08820139.2018.1504300","volume":"47","author":"Mohammadi S.,","year":"2018","unstructured":"Mohammadi S.,; V.; Ravari, A.; Mirzaei, T.; Zare-Bidaki, M.; Asadikaram, G.; Arababadi, M.K. IL-17A and IL-23: Plausible risk factors to induce age-associated inflammation in Alzheimer\u2019s disease. Immunol Invest  2018,47(8),812-822","journal-title":"Immunol Invest"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00281-016-0615-8","volume":"39","author":"Biragyn A.","year":"2017","unstructured":"Biragyn A.; Aliseychik M.; Rogaev E.; Potential importance of B cells in aging and aging-associated neurodegenerative diseases. Semin Immunopathol  2017,39(3),283-294","journal-title":"Semin Immunopathol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41583-019-0233-2","volume":"20","author":"Sabatino J.J.","year":"2019","unstructured":"Sabatino J.J.; Pr\u00f6bstel A.K.; Zamvil S.S.; B cells in autoimmune and neurodegenerative central nervous system diseases. Nat Rev Neurosci  2019,20(12),728-745","journal-title":"Nat Rev Neurosci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1093\/brain\/awh625","volume":"128","author":"Orr C.F.","year":"2005","unstructured":"Orr C.F.; Rowe D.B.; Mizuno Y.; Mori H.; Halliday G.M.; A possible role for humoral immunity in the pathogenesis of Parkinson\u2019s disease. Brain  2005,128(11),2665-2674","journal-title":"Brain"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1212\/WNL.57.5.801","volume":"57","author":"Du Y.","year":"2001","unstructured":"Du Y.; Dodel R.; Hampel H.; Buerger K.; Lin S.; Eastwood B.; Bales K.; Gao F.; Moeller H.J.; Oertel W.; Farlow M.; Paul S.; Reduced levels of amyloid -peptide antibody in Alzheimer disease. Neurology  2001,57(5),801-805","journal-title":"Neurology"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/ana.1061","volume":"49","author":"Hyman B.T.","year":"2001","unstructured":"Hyman B.T.; Smith C.; Buldyrev I.; Whelan C.; Brown H.; Tang M.X.; Mayeux R.; Autoantibodies to amyloid-? and Alzheimer\u2019s disease. Ann Neurol  2001,49(6),808-810","journal-title":"Ann Neurol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S0531-5565(02)00029-3","volume":"37","author":"Weksler M.E.","year":"2002","unstructured":"Weksler M.E.; Relkin N.; Turkenich R.; LaRusse S.; Zhou L.; Szabo P.; Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol  2002,37(7),943-948","journal-title":"Exp Gerontol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3233\/JAD-221091","volume":"92","author":"DeMarshall C.A.","year":"2023","unstructured":"DeMarshall C.A.; Viviano J.; Emrani S.; Thayasivam U.; Godsey G.A.; Sarkar A.; Belinka B.; Libon D.J.; Nagele R.G.; Early detection of alzheimer\u2019s disease-related pathology using a multi-disease diagnostic platform employing autoantibodies as blood-based biomarkers. J Alzheimers Dis  2023,92(3),1077-1091","journal-title":"J Alzheimers Dis"},{"key":"ref=147","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.5_Suppl_2.53","volume":"41","author":"Carvey P.M.","year":"1991","unstructured":"Carvey P.M.; McRae A.; Lint T.F.; Ptak L.R.; Lo E.S.; Goetz C.G.; Klawans H.L.;  The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson\u2019s disease  (5, Supplement 2)(2), 53-58.1991,41","journal-title":"The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson\u2019s disease"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1001\/archneur.55.8.1075","volume":"55","author":"Chen S.","year":"1998","unstructured":"Chen S.; Le W.D.; Xie W.J.; Alexianu M.E.; Engelhardt J.I.; Sikl\u00f3s L.; Appel S.H.; Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch Neurol  1998,55(8),1075-1080","journal-title":"Arch Neurol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/archneur.56.2.194","volume":"56","author":"Le W.D.","year":"1999","unstructured":"Le W.D.; Rowe D.B.; Jankovic J.; Xie W.; Appel S.H.; Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol  1999,56(2),194-200","journal-title":"Arch Neurol"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1471-4159.2006.04365.x","volume":"101","author":"Papachroni K.K.","year":"2007","unstructured":"Papachroni K.K.; Ninkina N.; Papapanagiotou A.; Hadjigeorgiou G.M.; Xiromerisiou G.; Papadimitriou A.; Kalofoutis A.; Buchman V.L.; Autoantibodies to alpha-synuclein in inherited Parkinson\u2019s disease. J Neurochem  2007,101(3),749-756","journal-title":"J Neurochem"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3389\/fneur.2017.00720","volume":"8","author":"Shalash A.","year":"2017","unstructured":"Shalash A.; Salama M.; Makar M.; Roushdy T.; Elrassas H.H.; Mohamed W.; El-Balkimy M.; Abou D.M.; Elevated serum \u03b1-synuclein autoantibodies in patients with Parkinson\u2019s disease relative to Alzheimer\u2019s disease and controls. Front Neurol  2017,8,720","journal-title":"Front Neurol"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1212\/WNL.0b013e31827b90d1","volume":"80","author":"Besong-Agbo D.","year":"2013","unstructured":"Besong-Agbo D.; Wolf E.; Jessen F.; Oechsner M.; Hametner E.; Poewe W.; Reindl M.; Oertel W.H.; Noelker C.; Bacher M.; Dodel R.; Naturally occurring -synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology  2013,80(2),169-175","journal-title":"Neurology"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1021\/acschemneuro.7b00063","volume":"8","author":"Horvath I.","year":"2017","unstructured":"Horvath I.; Iashchishyn I.A.; Forsgren L.; Morozova-Roche L.A.; Immunochemical detection of \u03b1-synuclein autoantibodies in Parkinson\u2019s disease: Correlation between plasma and cerebrospinal fluid levels. ACS Chem Neurosci  2017,8(6),1170-1176","journal-title":"ACS Chem Neurosci"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/jnc.14330","volume":"145","author":"Akhtar R.S.","year":"2018","unstructured":"Akhtar R.S.; Licata J.P.; Luk K.C.; Shaw L.M.; Trojanowski J.Q.; Lee V.M.Y.; Measurements of auto-antibodies to \u03b1-synuclein in the serum and cerebral spinal fluids of patients with Parkinson\u2019s disease. J Neurochem  2018,145(6),489-503","journal-title":"J Neurochem"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.expneurol.2009.03.002","volume":"217","author":"Double K.L.","year":"2009","unstructured":"Double K.L.; Rowe D.B.; Carew-Jones F.M.; Hayes M.; Chan D.K.Y.; Blackie J.; Corbett A.; Joffe R.; Fung V.S.; Morris J.; Riederer P.; Gerlach M.; Halliday G.M.; Anti-melanin antibodies are increased in sera in Parkinson\u2019s disease. Exp Neurol  2009,217(2),297-301","journal-title":"Exp Neurol"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1034\/j.1600-0404.2002.01240.x","volume":"106","author":"Zappia M.","year":"2002","unstructured":"Zappia M.; Crescibene L.; Bosco D.; Arabia G.; Nicoletti G.; Bagal\u00e0 A.; Bastone L.; Napoli I.D.; Caracciolo M.; Bonavita S.; Di Costanzo A.; Gambardella A.; Quattrone A.; Anti-GM1 ganglioside antibodies in Parkinson\u2019s disease. Acta Neurol Scand  2002,106(1),54-57","journal-title":"Acta Neurol Scand"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.autrev.2016.07.022","volume":"15","author":"De Virgilio A.","year":"2016","unstructured":"De Virgilio A.; Greco A.; Fabbrini G.; Inghilleri M.; Rizzo M.I.; Gallo A.; Conte M.; Rosato C.; Ciniglio Appiani M.; de Vincentiis M.; Parkinson\u2019s disease: Autoimmunity and neuroinflammation. Autoimmun Rev  2016,15(10),1005-1011","journal-title":"Autoimmun Rev"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12016-010-8242-y","volume":"42","author":"Benkler M.","year":"2012","unstructured":"Benkler M.; Agmon-Levin N.; Hassin-Baer S.; Cohen O.S.; Ortega-Hernandez O.D.; Levy A.; Moscavitch S.D.; Szyper-Kravitz M.; Damianovich M.; Blank M.; Chapman J.; Shoenfeld Y.; Immunology, autoimmunity, and autoantibodies in Parkinson\u2019s disease. Clin Rev Allergy Immunol  2012,42(2),164-171","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00702-016-1632-4","volume":"124","year":"2017","unstructured":"Papu\u0107, E.; Rejdak, K. Anti-MAG autoantibodies are increased in Parkinson\u2019s disease but not in atypical parkinsonism. J Neural Transm  2017,124(2),209-216","journal-title":"J Neural Transm"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11910-017-0709-2","volume":"17","author":"Honorat J.A.","year":"2017","unstructured":"Honorat J.A.; McKeon A.; Autoimmune movement disorders: A clinical and laboratory approach. Curr Neurol Neurosci Rep  2017,17(1),4","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jneuroim.2016.01.007","volume":"291","author":"Caggiu E.","year":"2016","unstructured":"Caggiu E.; Paulus K.; Arru G.; Piredda R.; Sechi G.P.; Sechi L.A.; Humoral cross reactivity between \u03b1-synuclein and herpes simplex-1 epitope in Parkinson\u2019s disease, a triggering role in the disease? J Neuroimmunol  2016,291,110-114","journal-title":"J Neuroimmunol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1038\/ncomms4633","volume":"5","author":"Cebri\u00e1n C.","year":"2014","unstructured":"Cebri\u00e1n C.; Zucca F.A.; Mauri P.; Steinbeck J.A.; Studer L.; Scherzer C.R.; Kanter E.; Budhu S.; Mandelbaum J.; Vonsattel J.P.; Zecca L.; Loike J.D.; Sulzer D.; MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration. Nat Commun  2014,5(1),3633","journal-title":"Nat Commun"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3389\/fimmu.2018.02047","volume":"9","author":"Jiang T.","year":"2018","unstructured":"Jiang T.; Li G.; Xu J.; Gao S.; Chen X.; The challenge of the pathogenesis of parkinson\u2019s disease: Is autoimmunity the culprit? Front Immunol  2018,9,2047","journal-title":"Front Immunol"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1471-2202-12-116","volume":"12","author":"Oberl\u00e4nder U.","year":"2011","unstructured":"Oberl\u00e4nder U.; Pletinckx K.; D\u00f6hler A.; M\u00fcller N.; Lutz M.B.; Arzberger T.; Riederer P.; Gerlach M.; Koutsilieri E.; Scheller C.; Neuromelanin is an immune stimulator for dendritic cells in vitro. BMC Neurosci  2011,12(1),116","journal-title":"BMC Neurosci"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00702-012-0842-7","volume":"120","author":"Koutsilieri E.","year":"2013","unstructured":"Koutsilieri E.; Lutz M.B.; Scheller C.; Autoimmunity, dendritic cells and relevance for Parkinson\u2019s disease. J Neural Transm  2013,120(1),75-81","journal-title":"J Neural Transm"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/NEN.0b013e31820805b9","volume":"70","author":"Depboylu C.","year":"2011","unstructured":"Depboylu C.; Sch\u00e4fer M.K.H.; Arias-Carri\u00f3n O.; Oertel W.H.; Weihe E.; H\u00f6glinger G.U.; Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease. J Neuropathol Exp Neurol  2011,70(2),125-132","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2174\/1567205015666180119104825","volume":"15","author":"Alberici A.","year":"2018","unstructured":"Alberici A.; Cristillo V.; Gazzina S.; Benussi A.; Padovani A.; Borroni B.; Autoimmunity and frontotemporal dementia. Curr Alzheimer Res  2018,15(7),602-609","journal-title":"Curr Alzheimer Res"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.neurobiolaging.2019.10.015","volume":"86","author":"Palese F.","year":"2020","unstructured":"Palese F.; Bonomi E.; Nuzzo T.; Benussi A.; Mellone M.; Zianni E.; Cisani F.; Casamassa A.; Alberici A.; Scheggia D.; Padovani A.; Marcello E.; Di Luca M.; Pittaluga A.; Usiello A.; Borroni B.; Gardoni F.; Anti-GluA3 antibodies in frontotemporal dementia: Effects on glutamatergic neurotransmission and synaptic failure. Neurobiol Aging  2020,86,143-155","journal-title":"Neurobiol Aging"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000517238","volume":"50","author":"Arshad F.","year":"2021","unstructured":"Arshad F.; Varghese F.; Paplikar A.; Gangadhar Y.; Ramakrishnan S.; Chaudhuri J.R.; Mahadevan A.; Alladi S.; Role of autoantibodies in neurodegenerative dementia: An emerging association. Dement Geriatr Cogn Disord  2021,50(2),153-160","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"e68996","DOI":"10.1371\/journal.pone.0068996","volume":"8","author":"Maftei M.","year":"2013","unstructured":"Maftei M.; Thurm F.; Schnack C.; Tumani H.; Otto M.; Elbert T.; Kolassa I.T.; Przybylski M.; Manea M.; von Arnim C.A.F.; Increased levels of antigen-bound \u03b2-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer\u2019s disease patients. PLoS One  2013,8(7),e68996","journal-title":"PLoS One"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3233\/JAD-180039","volume":"64","author":"Bartos A.","year":"2018","unstructured":"Bartos A.; Fialov\u00e1 L.; \u0160varcov\u00e1 J.; Lower serum antibodies against tau protein and heavy neurofilament in alzheimer\u2019s disease. J Alzheimers Dis  2018,64(3),751-760","journal-title":"J Alzheimers Dis"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3233\/JAD-2011-101845","volume":"25","author":"Koval L.","year":"2011","unstructured":"Koval L.; Lykhmus O.; Kalashnyk O.; Bachinskaya N.; Kravtsova G.; Soldatkina M.; Zouridakis M.; Stergiou C.; Tzartos S.; Tsetlin V.; Komisarenko S.; Skok M.; The presence and origin of autoantibodies against \u03b14 and \u03b17 nicotinic acetylcholine receptors in the human blood: Possible relevance to Alzheimer\u2019s pathology. J Alzheimers Dis  2011,25(4),747-761","journal-title":"J Alzheimers Dis"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1023\/A:1020692218416","volume":"134","author":"Davydova T.V.","year":"2002","unstructured":"Davydova T.V.; Mikovskaya O.I.; Fomina V.G.; Voskresenskaya N.I.; Doronina O.A.; Induction of immune complexes and autoantibodies to serotonin and dopamine in patients with Alzheimer\u2019s disease. Bull Exp Biol Med  2002,134(1),23-25","journal-title":"Bull Exp Biol Med"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10517-009-0530-2","volume":"147","author":"Davydova T.V.","year":"2009","unstructured":"Davydova T.V.; Voskresenskaya N.I.; Gorbatov V.Y.; Fomina V.G.; Doronina O.A.; Maksunova I.V.; Production of autoantibodies to glutamate during Alzheimer\u2019s dementia. Bull Exp Biol Med  2009,147(4),405-407","journal-title":"Bull Exp Biol Med"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.neures.2014.06.002","volume":"85","author":"Busse S.","year":"2014","unstructured":"Busse S.; Brix B.; Kunschmann R.; Bogerts B.; Stoecker W.; Busse M.; N-methyl-d-aspartate glutamate receptor (NMDA-R) antibodies in mild cognitive impairment and dementias. Neurosci Res  2014,85,58-64","journal-title":"Neurosci Res"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jneuroim.2007.03.023","volume":"186","author":"Gruden M.A.","year":"2007","unstructured":"Gruden M.A.; Davidova T.B.; Mali\u0161auskas M.; Sewell R.D.E.; Voskresenskaya N.I.; Wilhelm K.; Elistratova E.I.; Sherstnev V.V.; Morozova-Roche L.A.; Differential neuroimmune markers to the onset of Alzheimer\u2019s disease neurodegeneration and dementia: Autoantibodies to A\u03b2(25\u201335) oligomers, S100b and neurotransmitters. J Neuroimmunol  2007,186(1-2),181-192","journal-title":"J Neuroimmunol"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/0889-1591(92)90049-T","volume":"6","author":"Mecocci P.","year":"1992","unstructured":"Mecocci P.; Parnetti L.; Donato R.; Santucci C.; Santucci A.; Cadini D.; Fo\u00e0 E.; Cecchetti R.; Senin U.; Serum autoantibodies against glial fibrillary acidic protein in brain aging and senile dementias. Brain Behav Immun  1992,6(3),286-292","journal-title":"Brain Behav Immun"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0166-4328(93)90139-H","volume":"57","author":"McRae A.","year":"1993","unstructured":"McRae A.; Dahlstr\u00f6m A.; Polinsky R.; Ling E.A.; Cerebrospinal fluid microglial antibodies: Potential diagnostic markers for immune mechanisms in Alzheimer\u2019s disease. Behav Brain Res  1993,57(2),225-234","journal-title":"Behav Brain Res"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0165-5728(88)90038-0","volume":"19","author":"Kingsley B.S.","year":"1988","unstructured":"Kingsley B.S.; Gaskin F.; Fu S.M.; Human antibodies to neurofibrillary tangles and astrocytes in Alzheimer\u2019s disease. J Neuroimmunol  1988,19(1-2),89-99","journal-title":"J Neuroimmunol"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.nbd.2008.12.001","volume":"33","author":"Kankaanp\u00e4 J.","year":"2009","unstructured":"Kankaanp\u00e4 J.; Turunen S.P.; Moilanen V.; H\u00f6rkk\u00f6 S.; Remes A.M.; Cerebrospinal fluid antibodies to oxidized LDL are increased in Alzheimer\u2019s disease. Neurobiol Dis  2009,33(3),467-472","journal-title":"Neurobiol Dis"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1672568","volume":"2018","author":"Vojdani A.","year":"2018","unstructured":"Vojdani A.; Vojdani E.; Amyloid-Beta 1-42 cross-reactive antibody prevalent in human sera may contribute to intraneuronal deposition of A-Beta-P-42. Int J Alzheimers Dis  2018,2018,1-12","journal-title":"Int J Alzheimers Dis"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/156720506777632899","volume":"3","author":"Mruthinti S.","year":"2006","unstructured":"Mruthinti S.; Schade R.; Harrell D.; Gulati N.; Swamy-Mruthinti S.; Lee G.; Buccafusco J.; Autoimmunity in Alzheimer\u2019s disease as evidenced by plasma immunoreactivity against RAGE and Abeta42: Complication of diabetes. Curr Alzheimer Res  2006,3(3),229-235","journal-title":"Curr Alzheimer Res"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JAD-150053","volume":"47","author":"Giil L.M.","year":"2015","unstructured":"Giil L.M.; Kristoffersen E.K.; Vedeler C.A.; Aarsland D.; Nordrehaug J.E.; Winblad B.; Cedazo-Minguez A.; Lund A.; Reksten T.R.; Autoantibodies toward the angiotensin 2 Type 1 receptor: A novel autoantibody in alzheimer\u2019s disease. J Alzheimers Dis  2015,47(2),523-529","journal-title":"J Alzheimers Dis"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.autrev.2010.07.008","volume":"9","author":"Colasanti T.","year":"2010","unstructured":"Colasanti T.; Barbati C.; Rosano G.; Malorni W.; Ortona E.; Autoantibodies in patients with Alzheimer\u2019s disease: Pathogenetic role and potential use as biomarkers of disease progression. Autoimmun Rev  2010,9(12),807-811","journal-title":"Autoimmun Rev"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-2275(20)34198-5","volume":"39","author":"Ariga T.","year":"1998","unstructured":"Ariga T.; Jarvis W.D.; Yu R.K.; Role of sphingolipid-mediated cell death in neurodegenerative diseases. J Lipid Res  1998,39(1),1-16","journal-title":"J Lipid Res"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"361","DOI":"10.7555\/JBR.30.20150131","volume":"30","author":"Jianming W.","year":"2016","unstructured":"Jianming W.; Ling L.; Autoantibodies in Alzheimer\u2019s disease: Potential biomarkers, pathogenic roles, and therapeutic implications. J Biomed Res  2016,30(5),361-372","journal-title":"J Biomed Res"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.neurobiolaging.2010.05.013","volume":"33","author":"Vacirca D.","year":"2012","unstructured":"Vacirca D.; Delunardo F.; Matarrese P.; Colasanti T.; Margutti P.; Siracusano A.; Pontecorvo S.; Capozzi A.; Sorice M.; Francia A.; Malorni W.; Ortona E.; Autoantibodies to the adenosine triphosphate synthase play a pathogenetic role in Alzheimer\u2019s disease. Neurobiol Aging  2012,33(4),753-766","journal-title":"Neurobiol Aging"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3233\/JAD-2012-121312","volume":"33","author":"Berry A.","year":"2012","unstructured":"Berry A.; Vacirca D.; Capoccia S.; Bellisario V.; Malorni W.; Ortona E.; Cirulli F.; Anti-ATP synthase autoantibodies induce neuronal death by apoptosis and impair cognitive performance in C57BL\/6J mice. J Alzheimers Dis  2012,33(2),317-321","journal-title":"J Alzheimers Dis"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JAD-150088","volume":"46","author":"Dinkins M.B.","year":"2015","unstructured":"Dinkins M.B.; Dasgupta S.; Wang G.; Zhu G.; He Q.; Kong J.N.; Bieberich E.; The 5XFAD mouse model of Alzheimer\u2019s disease exhibits an age-dependent increase in anti-ceramide IgG and exogenous administration of ceramide further increases anti-ceramide titers and amyloid plaque burden. J Alzheimers Dis  2015,46(1),55-61","journal-title":"J Alzheimers Dis"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000333222","volume":"10","author":"Li X.","year":"2012","unstructured":"Li X.; Sundquist J.; Sundquist K.; Subsequent risks of Parkinson disease in patients with autoimmune and related disorders: A nationwide epidemiological study from Sweden. Neurodegener Dis  2012,10(1-4),277-284","journal-title":"Neurodegener Dis"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1111\/ggi.13488","volume":"18","author":"Li X.","year":"2018","unstructured":"Li X.; Sundquist J.; Z\u00f6ller B.; Sundquist K.; Dementia and Alzheimer\u2019s disease risks in patients with autoimmune disorders. Geriatr Gerontol Int  2018,18(9),1350-1355","journal-title":"Geriatr Gerontol Int"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"fcac014","DOI":"10.1093\/braincomms\/fcac014","volume":"4","author":"Cho Y.Y.","year":"2022","unstructured":"Cho Y.Y.; Kim B.; Shin D.W.; Youn J.; Mok J.O.; Kim C.H.; Kim S.W.; Chung J.H.; Han K.; Kim T.H.; Graves\u2019 disease and the risk of Parkinson\u2019s disease: A Korean population-based study. Brain Commun  2022,4(1),fcac014","journal-title":"Brain Commun"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S1353-8020(99)00010-3","volume":"5","author":"Bonuccelli U.","year":"1999","unstructured":"Bonuccelli U.; D\u2019Avino C.; Caraccio N.; Del Guerra P.; Casolaro A.; Pavese N.; Del Dotto P.; Monzani F.; Thyroid function and autoimmunity in Parkinson\u2019s disease: A study of 101 patients. Parkinsonism Relat Disord  1999,5(1-2),49-53","journal-title":"Parkinsonism Relat Disord"},{"key":"ref=194","doi-asserted-by":"publisher","first-page":"863281","DOI":"10.3389\/fendo.2022.863281","volume":"13","author":"Charoenngam N.","year":"2022","unstructured":"Charoenngam N.; Rittiphairoj T.; Ponvilawan B.; Prasongdee K.; Thyroid dysfunction and risk of Parkinson\u2019s disease: A systematic review and meta-analysis. Front Endocrinol  2022,13,863281","journal-title":"Front Endocrinol"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jpsychires.2022.09.052","volume":"155","author":"Yeung C.H.C.","year":"2022","unstructured":"Yeung C.H.C.; Au Yeung S.L.; Schooling C.M.; Association of autoimmune diseases with Alzheimer\u2019s disease: A mendelian randomization study. J Psychiatr Res  2022,155,550-558","journal-title":"J Psychiatr Res"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4103\/0028-3886.173623","volume":"64","author":"Ungprasert P.","year":"2016","unstructured":"Ungprasert P.; Wijarnpreecha K.; Thongprayoon C.; Rheumatoid arthritis and the risk of dementia: A systematic review and meta-analysis. Neurol India  2016,64(1),56-61","journal-title":"Neurol India"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12888-022-04417-w","volume":"22","author":"McDowell B.","year":"2022","unstructured":"McDowell B.; Marr C.; Holmes C.; Edwards C.J.; Cardwell C.; McHenry M.; Meenagh G.; McGuinness B.; Prevalence of cognitive impairment in patients with rheumatoid arthritis: A cross sectional study. BMC Psychiatry  2022,22(1),777","journal-title":"BMC Psychiatry"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"Tansey M.G.","year":"2022","unstructured":"Tansey M.G.; Wallings R.L.; Houser M.C.; Herrick M.K.; Keating C.E.; Joers V.; Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol  2022,22(11),657-673","journal-title":"Nat Rev Immunol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"885179","DOI":"10.3389\/fneur.2022.885179","volume":"13","author":"Li D.","year":"2022","unstructured":"Li D.; Hong X.; Chen T.; Association between rheumatoid arthritis and risk of Parkinson\u2019s disease: A meta-analysis and systematic review. Front Neurol  2022,13,885179","journal-title":"Front Neurol"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"1103053","DOI":"10.3389\/fimmu.2023.1103053","volume":"14","author":"Li M.","year":"2023","unstructured":"Li M.; Wan J.; Xu Z.; Tang B.; The association between Parkinson\u2019s disease and autoimmune diseases: A systematic review and meta-analysis. Front Immunol  2023,14,1103053","journal-title":"Front Immunol"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"12861","DOI":"10.1038\/s41598-017-13168-8","volume":"7","author":"Policicchio S.","year":"2017","unstructured":"Policicchio S.; Ahmad A.N.; Powell J.F.; Proitsi P.; Rheumatoid arthritis and risk for Alzheimer\u2019s disease: A systematic review and meta-analysis and a Mendelian Randomization study. Sci Rep  2017,7(1),12861","journal-title":"Sci Rep"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"1087571","DOI":"10.3389\/fimmu.2023.1087571","volume":"14","author":"Cooper J.","year":"2023","unstructured":"Cooper J.; Pastorello Y.; Slevin M.; A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Front Immunol  2023,14,1087571","journal-title":"Front Immunol"},{"key":"ref=203","first-page":"302","volume":"52","author":"Karabay E.A.","year":"2018","unstructured":"Karabay E.A.; \u00c7erman A.A.;; Altunay, \u0130.K. Evaluation of comorbidities in patients with autoimmune bullous diseases: A retrospective study. Sisli Etfal Hastan Tip Bul  2018,52(4),302-306","journal-title":"Sisli Etfal Hastan Tip Bul"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12967-020-02629-w","volume":"18","author":"Yeh F.C.","year":"2020","unstructured":"Yeh F.C.; Chen H.C.; Chou Y.C.; Lin C.L.; Kao C.H.; Lo H.Y.; Liu F.C.; Yang T.Y.; Positive association of Parkinson\u2019s disease with ankylosing spondylitis: A nationwide population-based study. J Transl Med  2020,18(1),455","journal-title":"J Transl Med"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/apt.17119","volume":"56","author":"R\u00f8nnow Sand J.","year":"2022","unstructured":"R\u00f8nnow Sand J.; Troelsen F.S.; Horv\u00e1th-Puh\u00f3 E.; Henderson V.W.; S\u00f8rensen H.T.; Erichsen R.; Risk of dementia in patients with inflammatory bowel disease: A Danish population-based study. Aliment Pharmacol Ther  2022,56(5),831-843","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=206","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/gutjnl-2020-320789","volume":"70","author":"Zhang B.","year":"2021","unstructured":"Zhang B.; Wang H.E.; Bai Y.M.; Tsai S.J.; Su T.P.; Chen T.J.; Wang Y.P.; Chen M.H.; Inflammatory bowel disease is associated with higher dementia risk: A nationwide longitudinal study. Gut  2021,70(1),85-91","journal-title":"Gut"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.3390\/jcm11133704","volume":"11","author":"Szandruk-Bender M.","year":"2022","unstructured":"Szandruk-Bender M.; Wiatrak B.;; Szel\u0105g, A. The risk of developing Alzheimer\u2019s disease and Parkinson\u2019s disease in patients with inflammatory bowel disease: A meta-analysis. J Clin Med  2022,11(13),3704","journal-title":"J Clin Med"},{"key":"ref=208","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/MCG.0000000000001714","volume":"57","author":"Aggarwal M.","year":"2023","unstructured":"Aggarwal M.; Alkhayyat M.; Abou Saleh M.; Sarmini M.T.; Singh A.; Garg R.; Garg P.; Mansoor E.; Padival R.; Cohen B.L.; Alzheimer disease occurs more frequently in patients with inflammatory bowel disease. J Clin Gastroenterol  2023,57(5),501-507","journal-title":"J Clin Gastroenterol"},{"key":"ref=209","doi-asserted-by":"publisher","first-page":"956005","DOI":"10.3389\/fimmu.2022.956005","volume":"13","author":"Cui G.","year":"2022","unstructured":"Cui G.; Li S.; Ye H.; Yang Y.; Huang Q.; Chu Y.; Shi Z.; Zhang X.; Are neurodegenerative diseases associated with an increased risk of inflammatory bowel disease? A two-sample Mendelian randomization study. Front Immunol  2022,13,956005","journal-title":"Front Immunol"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"846005","DOI":"10.3389\/fgene.2022.846005","volume":"13","author":"Li H.","year":"2022","unstructured":"Li H.; Wen Z.; Effects of ulcerative colitis and Crohn\u2019s disease on neurodegenerative diseases: A Mendelian randomization study. Front Genet  2022,13,846005","journal-title":"Front Genet"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41531-022-00318-7","volume":"8","author":"Freuer D.","year":"2022","unstructured":"Freuer D.; Meisinger C.; Association between inflammatory bowel disease and Parkinson\u2019s disease: A Mendelian randomization study. NPJ Parkinsons Dis  2022,8(1),55","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"e568","DOI":"10.1212\/WNL.0000000000201489","volume":"100","author":"Huang J.","year":"2023","unstructured":"Huang J.; Su B.; Karhunen V.; Gill D.; Zuber V.; Ahola-Olli A.; Palaniswamy S.; Auvinen J.; Herzig K.H.; Kein\u00e4nen-Kiukaanniemi S.; Salmi M.; Jalkanen S.; Lehtim\u00e4ki T.; Salomaa V.; Raitakari O.T.; Matthews P.M.; Elliott P.; Tsilidis K.K.; Jarvelin M.; Tzoulaki I.; Dehghan A.; Inflammatory diseases, inflammatory biomarkers, and Alzheimer disease. Neurology  2023,100(6),e568-e581","journal-title":"Neurology"},{"key":"ref=213","doi-asserted-by":"publisher","first-page":"e2097","DOI":"10.1097\/MD.0000000000002097","volume":"94","author":"Liu F.C.","year":"2015","unstructured":"Liu F.C.; Huang W.Y.; Lin T.Y.; Shen C.H.; Chou Y.C.; Lin C.L.; Lin K.T.; Kao C.H.; Inverse association of Parkinson disease with systemic lupus erythematosus. Medicine  2015,94(46),e2097","journal-title":"Medicine"},{"key":"ref=214","doi-asserted-by":"publisher","first-page":"1054246","DOI":"10.3389\/fimmu.2022.1054246","volume":"13","author":"Wang Y.C.","year":"2022","unstructured":"Wang Y.C.; Lin M.S.; Huang A.P.H.; Wu C.C.; Kung W.M.; Association between systemic rheumatic diseases and dementia risk: A meta-analysis. Front Immunol  2022,13,1054246","journal-title":"Front Immunol"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"1063110","DOI":"10.3389\/fimmu.2022.1063110","volume":"13","author":"Jin T.","year":"2022","unstructured":"Jin T.; Huang W.; Cao F.; Yu X.; Guo S.; Ying Z.; Xu C.; Causal association between systemic lupus erythematosus and the risk of dementia: A Mendelian randomization study. Front Immunol  2022,13,1063110","journal-title":"Front Immunol"},{"key":"ref=216","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","volume":"60","author":"Chen H.","year":"2003","unstructured":"Chen H.; Zhang S.M.; Hern\u00e1n M.A.; Schwarzschild M.A.; Willett W.C.; Colditz G.A.; Speizer F.E.; Ascherio A.; Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol  2003,60(8),1059-1064","journal-title":"Arch Neurol"},{"key":"ref=217","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/ana.20682","volume":"58","author":"Chen H.","year":"2005","unstructured":"Chen H.; Jacobs E.; Schwarzschild M.A.; McCullough M.L.; Calle E.E.; Thun M.J.; Ascherio A.; Nonsteroidal antiinflammatory drug use and the risk for Parkinson\u2019s disease. Ann Neurol  2005,58(6),963-967","journal-title":"Ann Neurol"},{"key":"ref=218","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","volume":"74","author":"Gagne J.J.","year":"2010","unstructured":"Gagne J.J.; Power M.C.; Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology  2010,74(12),995-1002","journal-title":"Neurology"},{"key":"ref=219","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1212\/WNL.0b013e31820f2d79","volume":"76","author":"Gao X.","year":"2011","unstructured":"Gao X.; Chen H.; Schwarzschild M.A.; Ascherio A.; Use of ibuprofen and risk of Parkinson disease. Neurology  2011,76(10),863-869","journal-title":"Neurology"},{"key":"ref=220","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/mds.21782","volume":"23","author":"Powers K.M.","year":"2008","unstructured":"Powers K.M.; Kay D.M.; Factor S.A.; Zabetian C.P.; Higgins D.S.; Samii A.; Nutt J.G.; Griffith A.; Leis B.; Roberts J.W.; Martinez E.D.; Montimurro J.S.; Checkoway H.; Payami H.; Combined effects of smoking, coffee, and NSAIDs on Parkinson\u2019s disease risk. Mov Disord  2008,23(1),88-95","journal-title":"Mov Disord"},{"key":"ref=221","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/mds.28189","volume":"35","author":"San Luciano M.","year":"2020","unstructured":"San Luciano M.; Tanner C.M.; Meng C.; Marras C.; Goldman S.M.; Lang A.E.; Tolosa E.; Sch\u00fcle B.; Langston J.W.; Brice A.; Corvol J.C.; Goldwurm S.; Klein C.; Brockman S.; Berg D.; Brockmann K.; Ferreira J.J.; Tazir M.; Mellick G.D.; Sue C.M.; Hasegawa K.; Tan E.K.; Bressman S.; Saunders-Pullman R.; Saunders-Pullman R.; Raymond D.; Deik A.; Barrett M.J.; Cabassa J.; Groves M.; Hunt A.L.; Lubarr N.; Miravite J.; Palmese C.; Sachdev R.; Sarva H.; Severt L.; Shanker V.; Swan M.C.; Soto-Valencia J.; Johannes B.; Ortega R.; Ozelius L.; Bressman S.; Alcalay R.N.; Tang M-X.; Santana H.M.; Roos E.; Orbe-Reilly M.; Fahn S.; Cote L.; Waters C.; Mazzoni P.; Ford B.; Louis E.; Levy O.; Rosado L.; Ruiz D.; Dorovski T.; Clark L.; Marder K.S.; Corvol J-C.; Cormier F.; Bonnet A-M.; Welter M-L.; Mesnage V.; Vidailhet M.; Roze E.; Lacomblez L.; Grabli D.; Mart i Masso J.F.; Martinez J.R.; Mondragon R.E.; Alustiza A.E.; Pagola A.G.; Pont-Sunyer C.; Rolan D.V.; Fernandez-Santiago R.; Quintana M.; Fernandez M.; Maragall L.; Hentati F.; Farrer M.; Duda J.; Read M.; Middleton L.; Gibson R.; Trinh J.; Sassi S.B.; Zouari M.;; Rimamouri,; Farhat, E.; Nabli, F.; Aasly, J.; War\u00f8, B.J.; Andersen, S.; Bertoni, J.; Carter, J.; Elmer, L.; Jimenez, N.G.; Martin, W.; Pahwa, R.; Lyons, K.; Reich, S.; Rodnitzky, R.; Ramos, C.S.; Wojcieszek, J.; Mirelman, A.; Gurevich, T.; Shira, A.B.; Weisz, M.G.; Yasinovsky, K.; Zalis, M.; Thaler, A.; Orr-Urtreger, A.; Giladi, N.; Mountain, J.; Mestre, T.; Visanji, N.; Ghate, T.; Singerman, J.; Al Dakheel, A.; Connolly, B.S.; Gasser, T.; Brockmann, K.; Conley, E.D.; Mullins, M.E.; Northover, C.; Facheris, M.; Fiske, B.; Urkowiz, A. Nonsteroidal anti-inflammatory use and LRRK2 Parkinson\u2019s disease penetrance. Mov Disord  2020,35(10),1755-1764","journal-title":"Mov Disord"},{"key":"ref=222","doi-asserted-by":"publisher","first-page":"e12172","DOI":"10.1097\/MD.0000000000012172","volume":"97","author":"Ren L.","year":"2018","unstructured":"Ren L.; Yi J.; Yang J.; Li P.; Cheng X.; Mao P.; Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease. Medicine  2018,97(37),e12172","journal-title":"Medicine"},{"key":"ref=223","doi-asserted-by":"publisher","first-page":"e0256602","DOI":"10.1371\/journal.pone.0256602","volume":"16","author":"Brakedal B.","year":"2021","unstructured":"Brakedal B.; Tzoulis C.; Tysnes O.B.; Haugarvoll K.; NSAID use is not associated with Parkinson\u2019s disease incidence: A Norwegian Prescription Database study. PLoS One  2021,16(9),e0256602","journal-title":"PLoS One"},{"key":"ref=224","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s40263-016-0374-z","volume":"30","author":"Chou R.C.","year":"2016","unstructured":"Chou R.C.; Kane M.; Ghimire S.; Gautam S.; Gui J.; Treatment for rheumatoid arthritis and risk of Alzheimer\u2019s disease: A nested case\/control analysis. CNS Drugs  2016,30(11),1111-1120","journal-title":"CNS Drugs"},{"key":"ref=225","doi-asserted-by":"publisher","first-page":"e0229819","DOI":"10.1371\/journal.pone.0229819","volume":"15","author":"Zhou M.","year":"2020","unstructured":"Zhou M.; Xu R.; Kaelber D.C.; Gurney M.E.; Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer\u2019s disease in patients with rheumatoid arthritis and psoriasis. PLoS One  2020,15(3),e0229819","journal-title":"PLoS One"},{"key":"ref=226","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/alz.12465","volume":"18","author":"Zheng C.","year":"2022","unstructured":"Zheng C.; Fillmore N.R.; Ramos-Cejudo J.; Brophy M.; Osorio R.; Gurney M.E.; Qiu W.Q.; Au R.; Perry G.; Dubreuil M.; Chen S.G.; Qi X.; Davis P.B.; Do N.; Xu R.; Potential long-term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans. Alzheimers Dement  2022,18(6),1248-1259","journal-title":"Alzheimers Dement"},{"key":"ref=227","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13195-020-00606-5","volume":"12","author":"Newby D.","year":"2020","unstructured":"Newby D.; Prieto-Alhambra D.; Duarte-Salles T.; Ansell D.; Pedersen L.; van der Lei J.; Mosseveld M.; Rijnbeek P.; James G.; Alexander M.; Egger P.; Podhorna J.; Stewart R.; Perera G.; Avillach P.; Grosdidier S.; Lovestone S.; Nevado-Holgado A.J.; Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: A multi-national multi-database case-control study. Alzheimers Res Ther  2020,12(1),38","journal-title":"Alzheimers Res Ther"},{"key":"ref=228","doi-asserted-by":"publisher","first-page":"106325","DOI":"10.1016\/j.phrs.2022.106325","volume":"182","author":"Watad A.","year":"2022","unstructured":"Watad A.; McGonagle D.; Anis S.; Carmeli R.; Cohen A.D.; Tsur A.M.; Ben-Shabat N.; Luigi Bragazzi N.; Lidar M.; Amital H.; TNF inhibitors have a protective role in the risk of dementia in patients with ankylosing spondylitis: Results from a nationwide study. Pharmacol Res  2022,182,106325","journal-title":"Pharmacol Res"},{"key":"ref=229","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","volume":"75","author":"Peter I.","year":"2018","unstructured":"Peter I.; Dubinsky M.; Bressman S.; Park A.; Lu C.; Chen N.; Wang A.; Anti\u2013tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurol  2018,75(8),939-946","journal-title":"JAMA Neurol"},{"key":"ref=230","doi-asserted-by":"publisher","first-page":"e12163","DOI":"10.1002\/trc2.12163","volume":"7","author":"Kern D.M.","year":"2021","unstructured":"Kern D.M.; Lovestone S.; Cepeda M.S.; Treatment with TNF-\u03b1 inhibitors versus methotrexate and the association with dementia and Alzheimer\u2019s disease. Alzheimers Dement  2021,7(1),e12163","journal-title":"Alzheimers Dement"},{"key":"ref=231","doi-asserted-by":"publisher","first-page":"e226567","DOI":"10.1001\/jamanetworkopen.2022.6567","volume":"5","author":"Desai R.J.","year":"2022","unstructured":"Desai R.J.; Varma V.R.; Gerhard T.; Segal J.; Mahesri M.; Chin K.; Horton D.B.; Kim S.C.; Schneeweiss S.; Thambisetty M.; Comparative risk of Alzheimer disease and related dementia among Medicare beneficiaries with Rheumatoid Arthritis treated with targeted disease\/modifying antirheumatic agents. JAMA Netw Open  2022,5(4),e226567","journal-title":"JAMA Netw Open"},{"key":"ref=232","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214016","volume":"78","author":"Fardet L.","year":"2019","unstructured":"Fardet L.; Nazareth I.; Petersen I.; Chronic hydroxychloroquine\/chloroquine exposure for connective tissue diseases and risk of Alzheimer\u2019s disease: A population-based cohort study. Ann Rheum Dis  , 279.2-282.2019,78(2)","journal-title":"Ann Rheum Dis"},{"key":"ref=233","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1136\/annrheumdis-2019-216173","volume":"80","author":"Lai S.W.","year":"2021","unstructured":"Lai S.W.; Kuo Y.H.; Liao K.F.; Chronic hydroxychloroquine exposure and the risk of Alzheimer\u2019s disease. Ann Rheum Dis  2021,80(7),e105","journal-title":"Ann Rheum Dis"},{"key":"ref=234","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/s41380-022-01912-0","volume":"28","author":"Varma V.R.","year":"2023","unstructured":"Varma V.R.; Desai R.J.; Navakkode S.; Wong L.W.; Anerillas C.; Loeffler T.; Schilcher I.; Mahesri M.; Chin K.; Horton D.B.; Kim S.C.; Gerhard T.; Segal J.B.; Schneeweiss S.; Gorospe M.; Sajikumar S.; Thambisetty M.; Hydroxychloroquine lowers Alzheimer\u2019s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer\u2019s disease. Mol Psychiatry  2023,28(3),1312-1326","journal-title":"Mol Psychiatry"},{"key":"ref=235","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/jcm9061890","volume":"9","author":"Mathieu S.","year":"2020","unstructured":"Mathieu S.; Couderc M.; Pereira B.; Dubost J.J.; Malochet-Guinamand S.; Tournadre A.; Soubrier M.; Moisset X.; Prevalence of migraine and neuropathic pain in rheumatic diseases. J Clin Med  2020,9(6),1890","journal-title":"J Clin Med"},{"key":"ref=236","doi-asserted-by":"publisher","first-page":"865139","DOI":"10.3389\/fnins.2022.865139","volume":"16","author":"Wu L.","year":"2022","unstructured":"Wu L.; Xu Q.; Zhou M.; Chen Y.; Jiang C.; Jiang Y.; Lin Y.; He Q.; Zhao L.; Dong Y.; Liu J.; Chen W.; Plasma miR-153 and miR-223 levels as potential biomarkers in Parkinson\u2019s disease. Front Neurosci  2022,16,865139","journal-title":"Front Neurosci"},{"key":"ref=237","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s13577-017-0187-5","volume":"31","author":"Li D.","year":"2018","unstructured":"Li D.; Yang H.; Ma J.; Luo S.; Chen S.; Gu Q.; MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson\u2019s disease by targeting Nlrp3. Hum Cell  2018,31(2),106-115","journal-title":"Hum Cell"},{"key":"ref=238","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3233\/JAD-150065","volume":"47","author":"Taglialatela G.","year":"2015","unstructured":"Taglialatela G.; Rastellini C.; Cicalese L.; Reduced incidence of dementia in solid organ transplant patients treated with calcineurin inhibitors. J Alzheimers Dis  2015,47(2),329-333","journal-title":"J Alzheimers Dis"},{"key":"ref=239","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3233\/JAD-220361","volume":"88","author":"Bukhbinder A.S.","year":"2022","unstructured":"Bukhbinder A.S.; Ling Y.; Hasan O.; Jiang X.; Kim Y.; Phelps K.N.; Schmandt R.E.; Amran A.; Coburn R.; Ramesh S.; Xiao Q.; Schulz P.E.; Risk of Alzheimer\u2019s disease following influenza vaccination: A claims-based cohort study using propensity score matching. J Alzheimers Dis  2022,88(3),1061-1074","journal-title":"J Alzheimers Dis"},{"key":"ref=240","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/vaccines9050491","volume":"9","author":"Klinger D.","year":"2021","unstructured":"Klinger D.; Hill B.L.; Barda N.; Halperin E.; Gofrit O.N.; Greenblatt C.L.; Rappoport N.; Linial M.; Bercovier H.; Bladder cancer immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer\u2019s disease and Parkinson\u2019s disease. Vaccines,  2021,9(5),491","journal-title":"Vaccines,"},{"key":"ref=241","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10787-023-01163-7","volume":"31","author":"Al-kuraishy H.M.","year":"2023","unstructured":"Al-kuraishy H.M.; Al-Gareeb A.I.; Saad H.M.; Batiha G.E.S.; Long-term use of metformin and Alzheimer\u2019s disease: Beneficial or detrimental effects. Inflammopharmacology  2023,31(3),1107-1115","journal-title":"Inflammopharmacology"},{"key":"ref=242","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3233\/JAD-2006-9S330","volume":"9","author":"McGeer P.L.","year":"2006","unstructured":"McGeer P.L.; Rogers J.; McGeer E.G.; Inflammation, anti-inflammatory agents and Alzheimer disease: The last 12 years. J Alzheimers Dis  2006,9(s3)(Suppl.),271-276","journal-title":"J Alzheimers Dis"},{"key":"ref=243","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2165\/00003495-200363080-00001","volume":"63","author":"Launer L.J.","year":"2003","unstructured":"Launer L.J.; Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer\u2019s disease: dissecting the epidemiological evidence. Drugs  2003,63(8),731-739","journal-title":"Drugs"},{"key":"ref=244","doi-asserted-by":"publisher","first-page":"12504","DOI":"10.1038\/ncomms12504","volume":"7","author":"Daniels M.J.D.","year":"2016","unstructured":"Daniels M.J.D.; Rivers-Auty J.; Schilling T.; Spencer N.G.; Watremez W.; Fasolino V.; Booth S.J.; White C.S.; Baldwin A.G.; Freeman S.; Wong R.; Latta C.; Yu S.; Jackson J.; Fischer N.; Koziel V.; Pillot T.; Bagnall J.; Allan S.M.; Paszek P.; Galea J.; Harte M.K.; Eder C.; Lawrence C.B.; Brough D.; Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer\u2019s disease in rodent models. Nat Commun  2016,7(1),12504","journal-title":"Nat Commun"},{"key":"ref=245","doi-asserted-by":"publisher","first-page":"113756","DOI":"10.1016\/j.expneurol.2021.113756","volume":"343","author":"Annadurai N.","year":"2021","unstructured":"Annadurai N.; De Sanctis J.B.; Hajd\u00fach M.; Das V.; Tau secretion and propagation: Perspectives for potential preventive interventions in Alzheimer\u2019s disease and other tauopathies. Exp Neurol  2021,343,113756","journal-title":"Exp Neurol"},{"key":"ref=246","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.biochi.2022.05.013","volume":"200","author":"Annadurai N.","year":"2022","unstructured":"Annadurai N.; Malina L.; Malohlava J.; Hajd\u00fach M.; Das V.; Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation. Biochimie  2022,200,79-86","journal-title":"Biochimie"},{"key":"ref=247","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1111\/febs.16270","volume":"289","author":"Annadurai N.","year":"2022","unstructured":"Annadurai N.; Malina L.; Salmona M.; Diomede L.; Bastone A.; Cagnotto A.; Romeo M.; \u0160rejber M.; Berka K.; Otyepka M.; Hajd\u00fach M.; Das V.; Antitumour drugs targeting tau R3 VQIVYK and Cys322 prevent seeding of endogenous tau aggregates by exogenous seeds. FEBS J  2022,289(7),1929-1949","journal-title":"FEBS J"},{"key":"ref=248","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bbrc.2023.02.057","volume":"653","author":"Annadurai N.","year":"2023","unstructured":"Annadurai N.; Hrub\u00fd J.;; Kub\u00ed\u010dkov\u00e1, A.; Malina, L.; Hajd\u00fach, M.; Das, V. Time- and dose-dependent seeding tendency of exogenous tau R2 and R3 aggregates in cells. Biochem Biophys Res Commun  2023,653,102-105","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=249","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1742-2094-9-62","volume":"9","author":"Ferretti M.T.","year":"2012","unstructured":"Ferretti M.T.; Allard S.; Partridge V.; Ducatenzeiler A.; Cuello A.C.; Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer\u2019s disease-like amyloid pathology. J Neuroinflammation  2012,9(1),62","journal-title":"J Neuroinflammation"},{"key":"ref=250","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1001\/jamaneurol.2014.391","volume":"71","author":"Parashos S.A.","year":"2014","unstructured":"Parashos S.A.; Luo S.; Biglan K.M.; Bodis-Wollner I.; He B.; Liang G.S.; Ross G.W.; Tilley B.C.; Shulman L.M.; Measuring disease progression in early Parkinson disease. JAMA Neurol  2014,71(6),710-716","journal-title":"JAMA Neurol"},{"key":"ref=251","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","volume":"89","author":"Nassar N.N.","year":"2015","unstructured":"Nassar N.N.; Al-Shorbagy M.Y.; Arab H.H.; Abdallah D.M.; Saxagliptin: A novel antiparkinsonian approach. Neuropharmacology  2015,89,308-317","journal-title":"Neuropharmacology"},{"key":"ref=252","doi-asserted-by":"publisher","first-page":"107668","DOI":"10.1016\/j.neuropharm.2019.107668","volume":"157","author":"Chen S.","year":"2019","unstructured":"Chen S.; Zhou M.; Sun J.; Guo A.; Fernando R.L.; Chen Y.; Peng P.; Zhao G.; Deng Y.; DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling. Neuropharmacology  2019,157,107668","journal-title":"Neuropharmacology"},{"key":"ref=253","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.14336\/AD.2022.0325","volume":"13","author":"Yu H.","year":"2022","unstructured":"Yu H.; Sun T.; He X.; Wang Z.; Zhao K.; An J.; Wen L.; Li J.Y.; Li W.; Feng J.; Association between Parkinson\u2019s disease and diabetes mellitus: From epidemiology, pathophysiology and prevention to treatment. Aging Dis  2022,13(6),1591-1605","journal-title":"Aging Dis"},{"key":"ref=254","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.nurt.2008.05.003","volume":"5","author":"Landreth G.","year":"2008","unstructured":"Landreth G.; Jiang Q.; Mandrekar S.; Heneka M.; PPAR\u03b3 agonists as therapeutics for the treatment of Alzheimer\u2019s disease. Neurotherapeutics  2008,5(3),481-489","journal-title":"Neurotherapeutics"},{"key":"ref=255","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/appi.ajgp.13.11.950","volume":"13","author":"Watson G.S.","year":"2005","unstructured":"Watson G.S.; Cholerton B.A.; Reger M.A.; Baker L.D.; Plymate S.R.; Asthana S.; Fishel M.A.; Kulstad J.J.; Green P.S.; Cook D.G.; Kahn S.E.; Keeling M.L.; Craft S.; Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry  2005,13(11),950-958","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=256","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","volume":"6","author":"Risner M.E.","year":"2006","unstructured":"Risner M.E.; Saunders A.M.; Altman J F B.; Ormandy G.C.; Craft S.; Foley I.M.; Zvartau-Hind M.E.; Hosford D.A.; Roses A.D.; Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer\u2019s disease. Pharmacogenomics J  2006,6(4),246-254","journal-title":"Pharmacogenomics J"},{"key":"ref=257","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.2147\/DDDT.S367229","volume":"16","author":"Alhowail A.","year":"2022","unstructured":"Alhowail A.; Alsikhan R.; Alsaud M.; Aldubayan M.; Rabbani S.I.; Protective effects of pioglitazone on cognitive impairment and the underlying mechanisms: A review of literature. Drug Des Devel Ther  2022,16,2919-2931","journal-title":"Drug Des Devel Ther"},{"key":"ref=258","doi-asserted-by":"publisher","first-page":"602508","DOI":"10.3389\/fnins.2020.602508","volume":"14","author":"Zhou Y.","year":"2020","unstructured":"Zhou Y.; Chen Y.; Xu C.; Zhang H.; Lin C.; TLR4 targeting as a promising therapeutic strategy for Alzheimer disease treatment. Front Neurosci  2020,14,602508","journal-title":"Front Neurosci"},{"key":"ref=259","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3389\/fnins.2020.00444","volume":"14","author":"Cui W.","year":"2020","unstructured":"Cui W.; Sun C.; Ma Y.; Wang S.; Wang X.; Zhang Y.; Inhibition of TLR4 Induces M2 microglial polarization and provides neuroprotection via the NLRP3 inflammasome in Alzheimer\u2019s disease. Front Neurosci  2020,14,444","journal-title":"Front Neurosci"},{"key":"ref=260","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/cns.13086","volume":"25","author":"Jin X.","year":"2019","unstructured":"Jin X.; Liu M.Y.; Zhang D.F.; Zhong X.; Du K.; Qian P.; Yao W.F.; Gao H.; Wei M.J.; Baicalin mitigates cognitive impairment and protects neurons from microglia-mediated neuroinflammation via suppressing NLRP 3 inflammasomes and TLR 4\/NF\u03baB signaling pathway. CNS Neurosci Ther  2019,25(5),575-590","journal-title":"CNS Neurosci Ther"},{"key":"ref=261","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/eji.201545855","volume":"46","author":"Shi S.","year":"2016","unstructured":"Shi S.; Liang D.; Chen Y.; Xie Y.; Wang Y.; Wang L.; Wang Z.; Qiao Z.; Gx-50 reduces \u03b2-amyloid-induced TNF-\u03b1 IL-1\u03b2 NO, and PGE2 expression and inhibits NF-\u03baB signaling in a mouse model of Alzheimer\u2019s disease. Eur J Immunol  2016,46(3),665-676","journal-title":"Eur J Immunol"},{"key":"ref=262","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-018-0276-2","volume":"13","author":"Kim C.","year":"2018","unstructured":"Kim C.; Spencer B.; Rockenstein E.; Yamakado H.; Mante M.; Adame A.; Fields J.A.; Masliah D.; Iba M.; Lee H.J.; Rissman R.A.; Lee S.J.; Masliah E.; Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating \u03b1-synuclein transmission and neuroinflammation. Mol Neurodegener  2018,13(1),43","journal-title":"Mol Neurodegener"},{"key":"ref=263","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/acel.13332","volume":"20","author":"Lee H.","year":"2021","unstructured":"Lee H.; Jeon S.G.; Kim J.; Kang R.J.; Kim S.M.; Han K.M.; Park H.; Kim K.; Sung Y.M.; Nam H.Y.; Koh Y.H.; Song M.; Suk K.; Hoe H.S.; Ibrutinib modulates A\u03b2\/tau pathology, neuroinflammation, and cognitive function in mouse models of Alzheimer\u2019s disease. Aging Cell  2021,20(3),e13332","journal-title":"Aging Cell"},{"key":"ref=264","doi-asserted-by":"publisher","first-page":"e55091","DOI":"10.1371\/journal.pone.0055091","volume":"8","author":"He P.","year":"2013","unstructured":"He P.; Cheng X.; Staufenbiel M.; Li R.; Shen Y.; Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of \u03b2-secretase in a mouse model of Alzheimer\u2019s disease. PLoS One  2013,8(2),e55091","journal-title":"PLoS One"},{"key":"ref=265","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1567205014666170117141330","volume":"14","author":"Decourt B.","year":"2017","unstructured":"Decourt B.; Drumm-Gurnee D.; Wilson J.; Jacobson S.; Belden C.; Sirrel S.; Ahmadi M.; Shill H.; Powell J.; Walker A.; Gonzales A.; Macias M.; Sabbagh M.N.; Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer\u2019s disease: Results from a double-blind, placebo-controlled trial. Curr Alzheimer Res  2017,14(4),403-411","journal-title":"Curr Alzheimer Res"},{"key":"ref=266","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/OAJCT.S221914","volume":"12","author":"Decourt B.","year":"2020","unstructured":"Decourt B.; Wilson J.; Ritter A.; Dardis C.; DiFilippo F.; Zhuang X.; Cordes D.; Lee G.; Fulkerson N.; St Rose T.; Hartley K.; Sabbagh M.; MCLENA-1: A phase ii clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to Alzheimer\u2019s disease. Open Access J Clin Trials  2020,12,1-13","journal-title":"Open Access J Clin Trials"},{"key":"ref=267","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13311-022-01182-2","volume":"19","author":"Palmas M.F.","year":"2022","unstructured":"Palmas M.F.; Ena A.; Burgaletto C.; Casu M.A.; Cantarella G.; Carboni E.; Etzi M.; De Simone A.; Fusco G.; Cardia M.C.; Lai F.; Picci L.; Tweedie D.; Scerba M.T.; Coroneo V.; Bernardini R.; Greig N.H.; Pisanu A.; Carta A.R.; Repurposing pomalidomide as a neuroprotective drug: Efficacy in an alpha-synuclein-based model of parkinson\u2019s disease. Neurotherapeutics  2022,19(1),305-324","journal-title":"Neurotherapeutics"},{"key":"ref=268","doi-asserted-by":"publisher","first-page":"175129","DOI":"10.1016\/j.ejphar.2022.175129","volume":"929","author":"Singh S.","year":"2022","unstructured":"Singh S.; Ganguly U.; Pal S.; Chandan G.; Thakur R.; Saini R.V.; Chakrabarti S.S.; Agrawal B.K.; Chakrabarti S.; Protective effects of cyclosporine A on neurodegeneration and motor impairment in rotenone-induced experimental models of Parkinson\u2019s disease. Eur J Pharmacol  2022,929,175129","journal-title":"Eur J Pharmacol"},{"key":"ref=269","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.neurobiolaging.2015.01.014","volume":"36","author":"Van der Perren A.","year":"2015","unstructured":"Van der Perren A.; Macchi F.; Toelen J.; Carlon M.S.; Maris M.; de Loor H.; Kuypers D.R.J.; Gijsbers R.; Van den Haute C.; Debyser Z.; Baekelandt V.; FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an \u03b1-synuclein-based rat model for Parkinson\u2019s disease. Neurobiol Aging  2015,36(3),1559-1568","journal-title":"Neurobiol Aging"},{"key":"ref=270","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3906\/sag-2008-291","volume":"51","author":"K\u00f6yl\u00fc A.","year":"2021","unstructured":"K\u00f6yl\u00fc A.; Altunkaynak B.Z.;; Deliba\u015f, B. Effects of tacrolimus on c-fos in hippocampus and memory performances in streptozotocin model of Alzheimer\u2019s disease of rats. Turk J Med Sci  2021,51(4),2159-2166","journal-title":"Turk J Med Sci"},{"key":"ref=271","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2174\/1567202615666180813125125","volume":"15","author":"Kumar A.","year":"2018","unstructured":"Kumar A.; Singh N.; Calcineurin inhibition and protein kinase a activation limits cognitive dysfunction and histopathological damage in a model of dementia of the Alzheimer\u2019s type. Curr Neurovasc Res  2018,15(3),234-245","journal-title":"Curr Neurovasc Res"},{"key":"ref=272","doi-asserted-by":"publisher","first-page":"1041006","DOI":"10.3389\/fcell.2022.1041006","volume":"10","author":"Lai W.D.","year":"2022","unstructured":"Lai W.D.; Wang S.; You W.T.; Chen S.J.; Wen J.J.; Yuan C.R.; Zheng M.J.; Jin Y.; Yu J.; Wen C.P.; Sinomenine regulates immune cell subsets: Potential neuro-immune intervene for precise treatment of chronic pain. Front Cell Dev Biol  2022,10,1041006","journal-title":"Front Cell Dev Biol"},{"key":"ref=273","first-page":"273","volume":"4","author":"Alam J.","year":"2017","unstructured":"Alam J.; Blackburn K.; Patrick D.; Neflamapimod: Clinical phase 2b-ready oral small molecule inhibitor of p38\u03b1 to reverse synaptic dysfunction in early Alzheimer\u2019s disease. J Prev Alzheimers Dis  2017,4(4),273-278","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=274","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13195-021-00843-2","volume":"13","author":"Prins N.D.","year":"2021","unstructured":"Prins N.D.; Harrison J.E.; Chu H.M.; Blackburn K.; Alam J.J.; Scheltens P.; A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer\u2019s disease. Alzheimers Res Ther  2021,13(1),106","journal-title":"Alzheimers Res Ther"},{"key":"ref=275","doi-asserted-by":"publisher","first-page":"e946","DOI":"10.1212\/NXI.0000000000000946","volume":"8","author":"Rothhammer V.","year":"2021","unstructured":"Rothhammer V.; Kenison J.E.; Li Z.; Tjon E.; Takenaka M.C.; Chao C.C.; Alves de Lima K.; Borucki D.M.; Kaye J.; Quintana F.J.; Aryl hydrocarbon receptor activation in astrocytes by laquinimod ameliorates autoimmune inflammation in the CNS. Neurol Neuroimmunol Neuroinflamm  2021,8(2),e946","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref=276","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/14728222.2021.1924151","volume":"25","author":"Srivastava S.","year":"2021","unstructured":"Srivastava S.; Rajopadhye R.; Dey M.; Singh R.K.; Inhibition of MK2 kinase as a potential therapeutic target to control neuroinflammation in Alzheimer\u2019s disease. Expert Opin Ther Targets  2021,25(4),243-247","journal-title":"Expert Opin Ther Targets"},{"key":"ref=277","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.1021\/acs.jmedchem.9b00058","volume":"62","author":"Roy S.M.","year":"2019","unstructured":"Roy S.M.; Minasov G.; Arancio O.; Chico L.W.; Van Eldik L.J.; Anderson W.F.; Pelletier J.C.; Watterson D.M.; A selective and brain penetrant p38\u03b1MAPK inhibitor candidate for neurologic and neuropsychiatric disorders that attenuates neuroinflammation and cognitive dysfunction. J Med Chem  2019,62(11),5298-5311","journal-title":"J Med Chem"},{"key":"ref=278","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2174\/1872213X13666190426164124","volume":"13","author":"Mart\u00ednez G.","year":"2019","unstructured":"Mart\u00ednez G.; Mijares M.R.; De Sanctis J.B.; Effects of flavonoids and its derivatives on immune cell responses. Recent Pat Inflamm Allergy Drug Discov  2019,13(2),84-104","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"ref=279","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10072-018-3592-y","volume":"40","author":"Ping Z.","year":"2019","unstructured":"Ping Z.; Xiaomu W.; Xufang X.; Liang S.; Vinpocetine regulates levels of circulating TLRs in Parkinson\u2019s disease patients. Neurol Sci  2019,40(1),113-120","journal-title":"Neurol Sci"},{"key":"ref=280","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1002\/ptr.6307","volume":"33","author":"Cui B.","year":"2019","unstructured":"Cui B.; Guo X.; You Y.; Fu R.; Farrerol attenuates MPP+induced inflammatory response by TLR4 signaling in a microglia cell line. Phytother Res  2019,33(4),1134-1141","journal-title":"Phytother Res"},{"key":"ref=281","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/ijms20030491","volume":"20","author":"Yang Y.L.","year":"2019","unstructured":"Yang Y.L.; Cheng X.; Li W.H.; Liu M.; Wang Y.H.; Du G.H.; Kaempferol attenuates LPS-induced striatum injury in mice involving anti-neuroinflammation, maintaining BBB integrity, and down-regulating the HMGB1\/TLR4 pathway. Int J Mol Sci  2019,20(3),491","journal-title":"Int J Mol Sci"},{"key":"ref=282","doi-asserted-by":"publisher","first-page":"104814","DOI":"10.1016\/j.nbd.2020.104814","volume":"140","author":"Yang L.","year":"2020","unstructured":"Yang L.; Zhou R.; Tong Y.; Chen P.; Shen Y.; Miao S.; Liu X.; Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation. Neurobiol Dis  2020,140,104814","journal-title":"Neurobiol Dis"},{"key":"ref=283","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.biopha.2018.05.020","volume":"104","author":"Haddadi R.","year":"2018","unstructured":"Haddadi R.; Nayebi A.M.; Eyvari B.S.; RETRACTED: Silymarin prevents apoptosis through inhibiting the Bax\/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats. Biomed Pharmacother  2018,104,127-136","journal-title":"Biomed Pharmacother"},{"key":"ref=284","doi-asserted-by":"publisher","first-page":"957705","DOI":"10.3389\/fnagi.2022.957705","volume":"14","author":"Su Q.","year":"2022","unstructured":"Su Q.; Ng W.L.; Goh S.Y.; Gulam M.Y.; Wang L.F.; Tan E.K.; Ahn M.; Chao Y.X.; Targeting the inflammasome in Parkinson\u2019s disease. Front Aging Neurosci  2022,14,957705","journal-title":"Front Aging Neurosci"},{"key":"ref=285","doi-asserted-by":"publisher","first-page":"e23045","DOI":"10.1002\/jbt.23045","volume":"36","author":"Yang Y.","year":"2022","unstructured":"Yang Y.; Guo L.; Wang J.; Li W.; Zhou X.; Zhang C.; Han C.; Arglabin regulates microglia polarization to relieve neuroinflammation in Alzheimer\u2019s disease. J Biochem Mol Toxicol  2022,36(6),e23045","journal-title":"J Biochem Mol Toxicol"},{"key":"ref=286","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12929-022-00871-6","volume":"29","author":"Tong B.C.K.","year":"2022","unstructured":"Tong B.C.K.; Huang A.S.; Wu A.J.; Iyaswamy A.; Ho O.K.Y.; Kong A.H.Y.; Sreenivasmurthy S.G.; Zhu Z.; Su C.; Liu J.; Song J.; Li M.; Cheung K.H.; Tetrandrine ameliorates cognitive deficits and mitigates tau aggregation in cell and animal models of tauopathies. J Biomed Sci  2022,29(1),85","journal-title":"J Biomed Sci"},{"key":"ref=287","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1016\/j.bbagen.2014.08.008","volume":"1840","author":"Velagapudi R.","year":"2014","unstructured":"Velagapudi R.; Aderogba M.; Olajide O.A.; Tiliroside, a dietary glycosidic flavonoid, inhibits TRAF-6\/NF-\u03baB\/p38-mediated neuroinflammation in activated BV2 microglia. Biochim Biophys Acta, Gen Subj  2014,1840(12),3311-3319","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"ref=288","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.3390\/molecules27206893","volume":"27","author":"Wu Q.","year":"2022","unstructured":"Wu Q.; Naeem A.; Zou J.; Yu C.; Wang Y.; Chen J.; Ping Y.; Isolation of phenolic compounds from raspberry based on molecular imprinting techniques and investigation of their anti-alzheimer\u2019s disease properties. Molecules  2022,27(20),6893","journal-title":"Molecules"},{"key":"ref=289","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1742-2094-5-41","volume":"5","author":"Rezai-Zadeh K.","year":"2008","unstructured":"Rezai-Zadeh K.; Ehrhart J.; Bai Y.; Sanberg P.R.; Bickford P.; Tan J.; Shytle R.D.; Apigenin and luteolin modulate microglial activation via inhibition of STAT1-induced CD40 expression. J Neuroinflammation  2008,5(1),41","journal-title":"J Neuroinflammation"},{"key":"ref=290","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JAD-2010-101593","volume":"24","author":"Liu R.","year":"2011","unstructured":"Liu R.; Zhang T.; Yang H.; Lan X.; Ying J.; Du G.; The flavonoid apigenin protects brain neurovascular coupling against amyloid-\u03b2\u2082\u2085\u208b\u2083\u2085-induced toxicity in mice. J Alzheimers Dis  2011,24(1),85-100","journal-title":"J Alzheimers Dis"},{"key":"ref=291","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.intimp.2013.09.009","volume":"17","author":"Kang C.H.","year":"2013","unstructured":"Kang C.H.; Choi Y.H.; Moon S.K.; Kim W.J.; Kim G.Y.; Quercetin inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglial cells by suppressing the NF-\u03baB pathway and activating the Nrf2-dependent HO-1 pathway. Int Immunopharmacol  2013,17(3),808-813","journal-title":"Int Immunopharmacol"},{"key":"ref=292","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/hup.1263","volume":"27","author":"Wightman E.L.","year":"2012","unstructured":"Wightman E.L.; Haskell C.F.; Forster J.S.; Veasey R.C.; Kennedy D.O.; Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. Hum Psychopharmacol  2012,27(2),177-186","journal-title":"Hum Psychopharmacol"},{"key":"ref=293","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s10787-020-00751-1","volume":"28","author":"Olajide O.A.","year":"2020","unstructured":"Olajide O.A.; Sarker S.D.; Alzheimer\u2019s disease: Natural products as inhibitors of neuroinflammation. Inflammopharmacology  2020,28(6),1439-1455","journal-title":"Inflammopharmacology"},{"key":"ref=294","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0779-0","volume":"14","author":"Moussa C.","year":"2017","unstructured":"Moussa C.; Hebron M.; Huang X.; Ahn J.; Rissman R.A.; Aisen P.S.; Turner R.S.; Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer\u2019s disease. J Neuroinflammation  2017,14(1),1","journal-title":"J Neuroinflammation"},{"key":"ref=295","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/biology8030051","volume":"8","author":"Porro C.","year":"2019","unstructured":"Porro C.; Cianciulli A.; Trotta T.; Lofrumento D.D.; Panaro M.A.; Curcumin regulates anti-inflammatory responses by JAK\/STAT\/SOCS signaling pathway in bv-2 microglial cells. Biology,  2019,8(3),51","journal-title":"Biology,"},{"key":"ref=296","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fphar.2018.00183","volume":"9","author":"Sorrenti V.","year":"2018","unstructured":"Sorrenti V.; Contarini G.; Sut S.; Dall\u2019Acqua S.; Confortin F.; Pagetta A.; Giusti P.; Zusso M.; Curcumin prevents acute neuroinflammation and long-term memory impairment induced by systemic lipopolysaccharide in mice. Front Pharmacol  2018,9,183","journal-title":"Front Pharmacol"},{"key":"ref=297","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3233\/JAD-170093","volume":"60","author":"Sundaram J.R.","year":"2017","unstructured":"Sundaram J.R.; Poore C.P.; Sulaimee N.H.B.; Pareek T.; Cheong W.F.; Wenk M.R.; Pant H.C.; Frautschy S.A.; Low C.M.; Kesavapany S.; Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of alzheimer\u2019s disease. J Alzheimers Dis  2017,60(4),1429-1442","journal-title":"J Alzheimers Dis"},{"key":"ref=298","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/alzrt146","volume":"4","author":"Ringman J.M.","year":"2012","unstructured":"Ringman J.M.; Frautschy S.A.; Teng E.; Begum A.N.; Bardens J.; Beigi M.; Gylys K.H.; Badmaev V.; Heath D.D.; Apostolova L.G.; Porter V.; Vanek Z.; Marshall G.A.; Hellemann G.; Sugar C.; Masterman D.L.; Montine T.J.; Cummings J.L.; Cole G.M.; Oral curcumin for Alzheimer\u2019s disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther  2012,4(5),43","journal-title":"Alzheimers Res Ther"},{"key":"ref=299","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1177\/0269881114552744","volume":"29","author":"Cox K.H.M.","year":"2015","unstructured":"Cox K.H.M.; Pipingas A.; Scholey A.B.; Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol  2015,29(5),642-651","journal-title":"J Psychopharmacol"},{"key":"ref=300","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jagp.2017.10.010","volume":"26","author":"Small G.W.","year":"2018","unstructured":"Small G.W.; Siddarth P.; Li Z.; Miller K.J.; Ercoli L.; Emerson N.D.; Martinez J.; Wong K.P.; Liu J.; Merrill D.A.; Chen S.T.; Henning S.M.; Satyamurthy N.; Huang S.C.; Heber D.; Barrio J.R.; Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial. Am J Geriatr Psychiatry  2018,26(3),266-277","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref=301","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12017-016-8434-6","volume":"19","author":"Khare P.","year":"2017","unstructured":"Khare P.; Datusalia A.K.; Sharma S.S.; Parthenolide, an NF-\u03baB Inhibitor ameliorates diabetes-induced behavioural deficit, neurotransmitter imbalance and neuroinflammation in type 2 diabetes rat model. Neuromol Med  2017,19(1),101-112","journal-title":"Neuromol Med"},{"key":"ref=302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2018.10.041","volume":"395","author":"Qiang W.","year":"2018","unstructured":"Qiang W.; Cai W.; Yang Q.; Yang L.; Dai Y.; Zhao Z.; Yin J.; Li Y.; Li Q.; Wang Y.; Weng X.; Zhang D.; Chen Y.; Zhu X.; Artemisinin B.; Artemisinin B.; Improves learning and memory impairment in AD dementia mice by suppressing neuroinflammation. Neuroscience  2018,395,1-12","journal-title":"Neuroscience"},{"key":"ref=303","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s12192-016-0728-y","volume":"21","author":"Zhou J.M.","year":"2016","unstructured":"Zhou J.M.; Gu S.S.; Mei W.H.; Zhou J.; Wang Z.Z.; Xiao W.; Ginkgolides and bilobalide protect BV2 microglia cells against OGD\/reoxygenation injury by inhibiting TLR2\/4 signaling pathways. Cell Stress Chaperones  2016,21(6),1037-1053","journal-title":"Cell Stress Chaperones"},{"key":"ref=304","doi-asserted-by":"publisher","first-page":"6155","DOI":"10.1007\/s12035-015-9519-1","volume":"53","author":"de Oliveira M.R.","year":"2016","unstructured":"de Oliveira M.R.; The dietary components carnosic acid and carnosol as neuroprotective agents: A Mechanistic View. Mol Neurobiol  2016,53(9),6155-6168","journal-title":"Mol Neurobiol"},{"key":"ref=305","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.intimp.2017.04.018","volume":"48","author":"Velagapudi R.","year":"2017","unstructured":"Velagapudi R.; Kumar A.; Bhatia H.S.; El-Bakoush A.; Lepiarz I.; Fiebich B.L.; Olajide O.A.; Inhibition of neuroinflammation by thymoquinone requires activation of Nrf2\/ARE signalling. Int Immunopharmacol  2017,48,17-29","journal-title":"Int Immunopharmacol"},{"key":"ref=306","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3892\/etm.2023.11934","volume":"25","author":"Yang W.","year":"2023","unstructured":"Yang W.; Qiu X.; Wu Q.; Chang F.; Zhou T.; Zhou M.; Pei J.; Active constituents of saffron (Crocus sativus L.) and their prospects in treating neurodegenerative diseases. (Review). Exp Ther Med  2023,25(5),235","journal-title":"Exp Ther Med"},{"key":"ref=307","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/1028415X.2022.2055376","volume":"26","author":"Fu M.","year":"2023","unstructured":"Fu M.; Liang X.; Zhang X.; Yang M.; Ye Q.; Qi Y.; Liu H.; Zhang X.; Astaxanthin delays brain aging in senescence-accelerated mouse prone 10: inducing autophagy as a potential mechanism. Nutr Neurosci  2023,26(5),445-455","journal-title":"Nutr Neurosci"},{"key":"ref=308","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.3390\/molecules27082507","volume":"27","author":"Lin C.H.","year":"2022","unstructured":"Lin C.H.; Chou C.C.; Lee Y.H.; Hung C.C.; Curcumin facilitates aryl hydrocarbon receptor activation to ameliorate inflammatory astrogliosis. Molecules  2022,27(8),2507","journal-title":"Molecules"},{"key":"ref=309","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"Hong S.","year":"2016","unstructured":"Hong S.; Beja-Glasser V.F.; Nfonoyim B.M.; Frouin A.; Li S.; Ramakrishnan S.; Merry K.M.; Shi Q.; Rosenthal A.; Barres B.A.; Lemere C.A.; Selkoe D.J.; Stevens B.; Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science  2016,352(6286),712-716","journal-title":"Science"},{"key":"ref=310","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"Pittock S.J.","year":"2019","unstructured":"Pittock S.J.; Berthele A.; Fujihara K.; Kim H.J.; Levy M.; Palace J.; Nakashima I.; Terzi M.; Totolyan N.; Viswanathan S.; Wang K.C.; Pace A.; Fujita K.P.; Armstrong R.; Wingerchuk D.M.; Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med  2019,381(7),614-625","journal-title":"N Engl J Med"},{"key":"ref=311","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.tips.2022.01.004","volume":"43","author":"Lamers C.","year":"2022","unstructured":"Lamers C.; Mastellos D.C.; Ricklin D.; Lambris J.D.; Compstatins: The dawn of clinical C3-targeted complement inhibition. Trends Pharmacol Sci  2022,43(8),629-640","journal-title":"Trends Pharmacol Sci"},{"key":"ref=312","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1091581817740873","volume":"36","author":"Lansita J.A.","year":"2017","unstructured":"Lansita J.A.; Mease K.M.; Qiu H.; Yednock T.; Sankaranarayanan S.; Kramer S.; Nonclinical development of ANX005: A humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol  2017,36(6),449-462","journal-title":"Int J Toxicol"},{"key":"ref=313","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nbd.2018.02.016","volume":"114","author":"Qi Y.","year":"2018","unstructured":"Qi Y.; Klyubin I.; Cuello A.C.; Rowan M.J.; NLRP3-dependent synaptic plasticity deficit in an Alzheimer\u2019s disease amyloidosis model in vivo. Neurobiol Dis  2018,114,24-30","journal-title":"Neurobiol Dis"},{"key":"ref=314","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/npp.2013.208","volume":"39","author":"Ben-Menachem-Zidon O.","year":"2014","unstructured":"Ben-Menachem-Zidon O.; Ben-Menahem Y.; Ben-Hur T.; Yirmiya R.; Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimer\u2019s disease model. Neuropsychopharmacology  2014,39(2),401-414","journal-title":"Neuropsychopharmacology"},{"key":"ref=315","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2016.07.009","volume":"47","author":"Cavanagh C.","year":"2016","unstructured":"Cavanagh C.; Tse Y.C.; Nguyen H.B.; Krantic S.; Breitner J.C.S.; Quirion R.; Wong T.P.; Inhibiting tumor necrosis factor-\u03b1 before amyloidosis prevents synaptic deficits in an Alzheimer\u2019s disease model. Neurobiol Aging  2016,47,41-49","journal-title":"Neurobiol Aging"},{"key":"ref=316","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ibror.2018.01.003","volume":"4","author":"Cavanagh C.","year":"2018","unstructured":"Cavanagh C.; Wong T.P.; Preventing synaptic deficits in Alzheimer\u2019s disease by inhibiting tumor necrosis factor alpha signaling. IBRO Rep  2018,4,18-21","journal-title":"IBRO Rep"},{"key":"ref=317","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.neuroscience.2021.11.001","volume":"484","author":"Li Y.","year":"2022","unstructured":"Li Y.; Fan H.; Ni M.; Zhang W.; Fang F.; Sun J.; Lyu P.; Ma P.; Etanercept reduces neuron injury and neuroinflammation via inactivating c-Jun N-terminal kinase and nuclear factor-\u03baB Pathways in Alzheimer\u2019s disease: An in vitro and in vivo investigation. Neuroscience  2022,484,140-150","journal-title":"Neuroscience"},{"key":"ref=318","first-page":"25","volume":"8","author":"Tobinick E.","year":"2006","unstructured":"Tobinick E.; Gross H.; Weinberger A.; Cohen H.; TNF-alpha modulation for treatment of Alzheimer\u2019s disease: A 6-month pilot study. MedGenMed  2006,8(2),25","journal-title":"MedGenMed"},{"key":"ref=319","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2377-8-27","volume":"8","author":"Tobinick E.L.","year":"2008","unstructured":"Tobinick E.L.; Gross H.; Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer\u2019s disease. BMC Neurol  2008,8,27","journal-title":"BMC Neurol"},{"key":"ref=320","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1212\/WNL.0000000000001617","volume":"84","author":"Butchart J.","year":"2015","unstructured":"Butchart J.; Brook L.; Hopkins V.; Teeling J.; P\u00fcntener U.; Culliford D.; Sharples R.; Sharif S.; McFarlane B.; Raybould R.; Thomas R.; Passmore P.; Perry V.H.; Holmes C.; Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology  2015,84(21),2161-2168","journal-title":"Neurology"},{"key":"ref=321","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000475736.75775.25","volume":"85","author":"Tufan A.N.","year":"2015","unstructured":"Tufan A.N.; Holmes C.; Tufan F.; Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trialAuthor Response. Neurology  , 2083.2-2084.2015,85(23)","journal-title":"Neurology"},{"key":"ref=322","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JAD-200711","volume":"78","author":"Torres-Acosta N.","year":"2020","unstructured":"Torres-Acosta N.; O\u2019Keefe J.H.; O\u2019Keefe E.L.; Isaacson R.; Small G.; Therapeutic potential of TNF-\u03b1 inhibition for Alzheimer\u2019s disease prevention. J Alzheimers Dis  2020,78(2),619-626","journal-title":"J Alzheimers Dis"},{"key":"ref=323","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/nm.2965","volume":"18","author":"vom Berg J.","year":"2012","unstructured":"vom Berg J.; Prokop S.; Miller K.R.; Obst J.; K\u00e4lin R.E.; Lopategui-Cabezas I.; Wegner A.; Mair F.; Schipke C.G.; Peters O.; Winter Y.; Becher B.; Heppner F.L.; Inhibition of IL-12\/IL-23 signaling reduces Alzheimer\u2019s disease-like pathology and cognitive decline. Nat Med  2012,18(12),1812-1819","journal-title":"Nat Med"},{"key":"ref=324","doi-asserted-by":"publisher","first-page":"14057","DOI":"10.1038\/s41598-017-14020-9","volume":"7","author":"Pedrini S.","year":"2017","unstructured":"Pedrini S.; Gupta V.B.; Hone E.; Doecke J.; O\u2019Bryant S.; James I.; Bush A.I.; Rowe C.C.; Villemagne V.L.; Ames D.; Masters C.L.; Martins R.N.; Savage G.; Wilson B.; Bourgeat P.; Fripp J.; Gibson S.; Leroux H.; McBride S.; Salvado O.; Fenech M.; Francois M.; Barnes M.; Baker J.; Barnham K.; Bellingham S.; Bomke J.; Pejoska S.B.; Buckley R.; Cheng L.; Collins S.; Cooke I.; Cyarto E.; Darby D.; Dore V.; El-Sheikh D.; Faux N.; Fowler C.; Harrington K.; Hill A.; Horne M.; Jones G.; Kamer A.; Killeen N.; Korrel H.; Lamb F.; Lautenschlager N.; Lennon K.; Li Q-X.; Lim Y.Y.; Louey A.; Macaulay L.; Mackintosh L.; Maruff P.; Mcilroy A.; Nigro J.; Perez K.; Pertile K.; Restrepo C.; Cardoso B.R.; Rembach A.; Roberts B.; Robertson J.; Rumble R.; Ryan T.; Sach J.; Silbert B.; Thai C.; Trounson B.; Volitakis I.; Vovos M.; Ward L.; Watt A.; Williams R.; Woodward M.; Yates P.; Ugarte F.Y.; Zhang P.; Bird S.; Brown B.; Burnham S.; Chatterjee P.; Cox K.; Fernandez S.; Fernando B.; Gardener S.; Laws S.; Lim F.; Lim L.; Tegg M.; Lucas K.; Martins G.; Porter T.; Rainey-Smith S.; Rodrigues M.; Shen K.K.; Sohrabi H.; Taddei K.; Taddei T.; Tan S.; Verdile G.; Weinborn M.; Farrow M.; Frost S.; Hanson D.; Hor M.; Kanagasingam Y.; Leifert W.; Lockett L.; Riley M.; Saunders I.; Thomas P.; A blood-based biomarker panel indicates IL-10 and IL-12\/23p40 are jointly associated as predictors of \u03b2-amyloid load in an AD cohort. Sci Rep  2017,7(1),14057","journal-title":"Sci Rep"},{"key":"ref=325","doi-asserted-by":"publisher","first-page":"e48530","DOI":"10.15252\/embr.201948530","volume":"21","author":"Eede P.","year":"2020","unstructured":"Eede P.; Obst J.; Benke E.; Yvon-Durocher G.; Richard B.C.; Gimber N.; Schmoranzer J.; B\u00f6ddrich A.; Wanker E.E.; Prokop S.; Heppner F.L.; Interleukin-\/23 deficiency differentially affects pathology in male and female Alzheimer\u2019s disease-like mice. EMBO Rep  2020,21(3),e48530","journal-title":"EMBO Rep"},{"key":"ref=326","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3390\/biom10071017","volume":"10","author":"Porro C.","year":"2020","unstructured":"Porro C.; Cianciulli A.; Panaro M.A.; The Regulatory Role of IL-10 in neurodegenerative diseases. Biomolecules  2020,10(7),1017","journal-title":"Biomolecules"},{"key":"ref=327","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s13643-022-02115-y","volume":"11","author":"Fei Z.","year":"2022","unstructured":"Fei Z.; Pan B.; Pei R.; Chen Z.; Du X.; Cao H.; Li C.; Efficacy and safety of blood derivatives therapy in Alzheimer\u2019s disease: A systematic review and meta-analysis. Syst Rev  2022,11(1),256","journal-title":"Syst Rev"},{"key":"ref=328","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"Rinne J.O.","year":"2010","unstructured":"Rinne J.O.; Brooks D.J.; Rossor M.N.; Fox N.C.; Bullock R.; Klunk W.E.; Mathis C.A.; Blennow K.; Barakos J.; Okello A.A.; de LIano, S.R.M.; Liu, E.; Koller, M.; Gregg, K.M.; Schenk, D.; Black, R.; Grundman, M. 11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer\u2019s disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol  2010,9(4),363-372","journal-title":"Lancet Neurol"},{"key":"ref=329","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"Vandenberghe R.","year":"2016","unstructured":"Vandenberghe R.; Rinne J.O.; Boada M.; Katayama S.; Scheltens P.; Vellas B.; Tuchman M.; Gass A.; Fiebach J.B.; Hill D.; Lobello K.; Li D.; McRae T.; Lucas P.; Evans I.; Booth K.; Luscan G.; Wyman B.T.; Hua L.; Yang L.; Brashear H.R.; Black R.S.; Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther  2016,8(1),18","journal-title":"Alzheimers Res Ther"},{"key":"ref=330","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13195-016-0177-y","volume":"8","author":"Delnomdedieu M.","year":"2016","unstructured":"Delnomdedieu M.; Duvvuri S.; Li D.J.; Atassi N.; Lu M.; Brashear H.R.; Liu E.; Ness S.; Kupiec J.W.; First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer\u2019s disease. Alzheimers Res Ther  2016,8(1),12","journal-title":"Alzheimers Res Ther"},{"key":"ref=331","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"Salloway S.","year":"2014","unstructured":"Salloway S.; Sperling R.; Brashear H.R.; Phase 3 trials of solanezumab and bapineuzumab for Alzheimer\u2019s disease. N Engl J Med  2014,370(15),1460","journal-title":"N Engl J Med"},{"key":"ref=332","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","year":"2014","unstructured":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med Bapineuzumab 301 and 302 Clinical Trial Investigators 2014,370(4),322-333","journal-title":"N Engl J Med"},{"key":"ref=333","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"Honig L.S.","year":"2018","unstructured":"Honig L.S.; Vellas B.; Woodward M.; Boada M.; Bullock R.; Borrie M.; Hager K.; Andreasen N.; Scarpini E.; Liu-Seifert H.; Case M.; Dean R.A.; Hake A.; Sundell K.; Poole Hoffmann V.; Carlson C.; Khanna R.; Mintun M.; DeMattos R.; Selzler K.J.; Siemers E.; Trial of solanezumab for mild dementia due to alzheimer\u2019s disease. N Engl J Med  2018,378(4),321-330","journal-title":"N Engl J Med"},{"key":"ref=334","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"Salloway S.","year":"2021","unstructured":"Salloway S.; Farlow M.; McDade E.; Clifford D.B.; Wang G.; Llibre-Guerra J.J.; Hitchcock J.M.; Mills S.L.; Santacruz A.M.; Aschenbrenner A.J.; Hassenstab J.; Benzinger T.L.S.; Gordon B.A.; Fagan A.M.; Coalier K.A.; Cruchaga C.; Goate A.A.; Perrin R.J.; Xiong C.; Li Y.; Morris J.C.; Snider B.J.; Mummery C.; Surti G.M.; Hannequin D.; Wallon D.; Berman S.B.; Lah J.J.; Jimenez-Velazquez I.Z.; Roberson E.D.; van Dyck C.H.; Honig L.S.; S\u00e1nchez-Valle R.; Brooks W.S.; Gauthier S.; Galasko D.R.; Masters C.L.; Brosch J.R.; Hsiung G.Y.R.; Jayadev S.; Formaglio M.; Masellis M.; Clarnette R.; Pariente J.; Dubois B.; Pasquier F.; Jack C.R.; Koeppe R.; Snyder P.J.; Aisen P.S.; Thomas R.G.; Berry S.M.; Wendelberger B.A.; Andersen S.W.; Holdridge K.C.; Mintun M.A.; Yaari R.; Sims J.R.; Baudler M.; Delmar P.; Doody R.S.; Fontoura P.; Giacobino C.; Kerchner G.A.; Bateman R.J.; Formaglio M.; Mills S.L.; Pariente J.; van Dyck C.H.; A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med  2021,27(7),1187-1196","journal-title":"Nat Med"},{"key":"ref=335","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/psp4.12912","volume":"12","author":"Geerts H.","year":"2023","unstructured":"Geerts H.; Walker M.; Rose R.; Bergeler S.; van der Graaf P.H.; Schuck E.; Koyama A.; Yasuda S.; Hussein Z.; Reyderman L.; Swanson C.; Cabal A.; A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer\u2019s disease. CPT Pharmacometrics Syst Pharmacol  2023,12(4),444-461","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=336","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1038\/s41598-020-60319-5","volume":"10","author":"Hettmann T.","year":"2020","unstructured":"Hettmann T.; Gillies S.D.; Kleinschmidt M.; Piechotta A.; Makioka K.; Lemere C.A.; Schilling S.; Rahfeld J.U.; Lues I.; Development of the clinical candidate PBD-C06, a humanized pGlu3-A\u03b2-specific antibody against Alzheimer\u2019s disease with reduced complement activation. Sci Rep  2020,10(1),3294","journal-title":"Sci Rep"},{"key":"ref=337","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"Mintun M.A.","year":"2021","unstructured":"Mintun M.A.; Lo A.C.; Duggan Evans C.; Wessels A.M.; Ardayfio P.A.; Andersen S.W.; Shcherbinin S.; Sparks J.; Sims J.R.; Brys M.; Apostolova L.G.; Salloway S.P.; Skovronsky D.M.; Donanemab in early Alzheimer\u2019s disease. N Engl J Med  2021,384(18),1691-1704","journal-title":"N Engl J Med"},{"key":"ref=338","first-page":"414","volume":"8","author":"Lowe S.L.","year":"2021","unstructured":"Lowe S.L.; Duggan Evans C.; Shcherbinin S.; Cheng Y.J.; Willis B.A.; Gueorguieva I.; Lo A.C.; Fleisher A.S.; Dage J.L.; Ardayfio P.; Aguiar G.; Ishibai M.; Takaichi G.; Chua L.; Mullins G.; Sims J.R.; Donanemab (LY3002813) Phase 1b study in alzheimer\u2019s disease: Rapid and sustained reduction of brain amyloid measured by florbetapir F18 Imaging. J Prev Alzheimers Dis  2021,8(4),414-424","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=339","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cpt.2875","volume":"113","author":"Gueorguieva I.","year":"2023","unstructured":"Gueorguieva I.; Willis B.A.; Chua L.; Chow K.; Ernest C.S.; Shcherbinin S.; Ardayfio P.; Mullins G.R.; Sims J.R.; Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer\u2019s disease. Clin Pharmacol Ther  2023,113(6),1258-1267","journal-title":"Clin Pharmacol Ther"},{"key":"ref=340","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"Sevigny J.","year":"2016","unstructured":"Sevigny J.; Chiao P.; Bussi\u00e8re T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O\u2019Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A.; The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature  2016,537(7618),50-56","journal-title":"Nature"},{"key":"ref=341","doi-asserted-by":"publisher","first-page":"8902","DOI":"10.3390\/ijms23168902","volume":"23","author":"Doroszkiewicz J.","year":"2022","unstructured":"Doroszkiewicz J.; Mroczko B.; New possibilities in the therapeutic approach to Alzheimer\u2019s disease. Int J Mol Sci  2022,23(16),8902","journal-title":"Int J Mol Sci"},{"key":"ref=342","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"S\u00f6derberg L.","year":"2023","unstructured":"S\u00f6derberg L.; Johannesson M.; Nygren P.; Laudon H.; Eriksson F.; Osswald G.; M\u00f6ller C.; Lannfelt L.; Lecanemab, aducanumab, and gantenerumab: Binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for alzheimer\u2019s disease. Neurotherapeutics  2023,20(1),195-206","journal-title":"Neurotherapeutics"},{"key":"ref=343","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3928\/00989134-20221205-02","volume":"49","author":"Brandt N.J.","year":"2023","unstructured":"Brandt N.J.; Wheeler C.; Courtin S.O.; Navigating disease-modifying treatments for Alzheimer\u2019s disease: Focusing on medications in phase 3 clinical trials. J Gerontol Nurs  2023,49(1),6-10","journal-title":"J Gerontol Nurs"},{"key":"ref=344","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4140\/TCP.n.2022.329","volume":"37","author":"Yuksel J.M.","year":"2022","unstructured":"Yuksel J.M.; Noviasky J.; Britton S.; Aducanumab for Alzheimer\u2019s disease: Summarized data from emerge, engage, and prime studies. Sr Care Pharm  2022,37(8),329-334","journal-title":"Sr Care Pharm"},{"key":"ref=345","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"Swanson C.J.","year":"2021","unstructured":"Swanson C.J.; Zhang Y.; Dhadda S.; Wang J.; Kaplow J.; Lai R.Y.K.; Lannfelt L.; Bradley H.; Rabe M.; Koyama A.; Reyderman L.; Berry D.A.; Berry S.; Gordon R.; Kramer L.D.; Cummings J.L.; A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther  2021,13(1),80","journal-title":"Alzheimers Res Ther"},{"key":"ref=346","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/alz.12748","volume":"19","author":"Rafii M.S.","year":"2023","unstructured":"Rafii M.S.; Sperling R.A.; Donohue M.C.; Zhou J.; Roberts C.; Irizarry M.C.; Dhadda S.; Sethuraman G.; Kramer L.D.; Swanson C.J.; Li D.; Krause S.; Rissman R.A.; Walter S.; Raman R.; Johnson K.A.; Aisen P.S.; The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer\u2019s disease. Alzheimers Dement  2023,19(4),1227-1233","journal-title":"Alzheimers Dement"},{"key":"ref=347","doi-asserted-by":"publisher","first-page":"100982","DOI":"10.1016\/j.xcrm.2023.100982","volume":"4","author":"Knopman D.S.","year":"2023","unstructured":"Knopman D.S.; Lecanemab reduces brain amyloid-\u03b2 and delays cognitive worsening. Cell Rep Med  2023,4(3),100982","journal-title":"Cell Rep Med"},{"key":"ref=348","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1126\/science.adi2242","volume":"380","author":"Piller C.","year":"2023","unstructured":"Piller C.; Report on trial death stokes Alzheimer\u2019s drug fears. Science  2023,380(6641),122-123","journal-title":"Science"},{"key":"ref=349","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","volume":"27","author":"Asuni A.A.","year":"2007","unstructured":"Asuni A.A.; Boutajangout A.; Quartermain D.; Sigurdsson E.M.; Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci  2007,27(34),9115-9129","journal-title":"J Neurosci"},{"key":"ref=350","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","volume":"118","author":"Boutajangout A.","year":"2011","unstructured":"Boutajangout A.; Ingadottir J.; Davies P.; Sigurdsson E.M.; Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem  2011,118(4),658-667","journal-title":"J Neurochem"},{"key":"ref=351","doi-asserted-by":"publisher","first-page":"eaal2029","DOI":"10.1126\/scitranslmed.aal2029","volume":"9","author":"Yanamandra K.","year":"2017","unstructured":"Yanamandra K.; Patel T.K.; Jiang H.; Schindler S.; Ulrich J.D.; Boxer A.L.; Miller B.L.; Kerwin D.R.; Gallardo G.; Stewart F.; Finn M.B.; Cairns N.J.; Verghese P.B.; Fogelman I.; West T.; Braunstein J.; Robinson G.; Keyser J.; Roh J.; Knapik S.S.; Hu Y.; Holtzman D.M.; Holtzman D.M.; Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy. Sci Transl Med  2017,9(386),eaal2029","journal-title":"Sci Transl Med"},{"key":"ref=352","doi-asserted-by":"publisher","first-page":"114337","DOI":"10.1016\/j.expneurol.2023.114337","volume":"362","author":"Li L.","year":"2023","unstructured":"Li L.; Miao J.; Jiang Y.; Dai C.L.; Iqbal K.; Liu F.; Chu D.; Passive immunization inhibits tau phosphorylation and improves recognition learning and memory in 3xTg-AD mice. Exp Neurol  2023,362,114337","journal-title":"Exp Neurol"},{"key":"ref=353","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","volume":"16","author":"Novak P.","year":"2017","unstructured":"Novak P.; Schmidt R.; Kontsekova E.; Zilka N.; Kovacech B.; Skrabana R.; Vince-Kazmerova Z.; Katina S.; Fialova L.; Prcina M.; Parrak V.; Dal-Bianco P.; Brunner M.; Staffen W.; Rainer M.; Ondrus M.; Ropele S.; Smisek M.; Sivak R.; Winblad B.; Novak M.; Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol  2017,16(2),123-134","journal-title":"Lancet Neurol"},{"key":"ref=354","first-page":"63","volume":"6","author":"Novak P.","year":"2019","unstructured":"Novak P.; Zilka N.; Zilkova M.; Kovacech B.; Skrabana R.; Ondrus M.; Fialova L.; Kontsekova E.; Otto M.; Novak M.; AADvac1, an active immunotherapy for Alzheimer\u2019s disease and non alzheimer tauopathies: An overview of preclinical and clinical development. J Prev Alzheimers Dis  2019,6(1),63-69","journal-title":"J Prev Alzheimers Dis"},{"key":"ref=355","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41541-022-00544-3","volume":"7","author":"Hovakimyan A.","year":"2022","unstructured":"Hovakimyan A.; Zagorski K.; Chailyan G.; Antonyan T.; Melikyan L.; Petrushina I.; Batt D.G.; King O.; Ghazaryan M.; Donthi A.; Foose C.; Petrovsky N.; Cribbs D.H.; Agadjanyan M.G.; Ghochikyan A.; Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates. NPJ Vaccines  2022,7(1),117","journal-title":"NPJ Vaccines"},{"key":"ref=356","doi-asserted-by":"publisher","first-page":"705407","DOI":"10.3389\/fneur.2021.705407","volume":"12","author":"Pagano G.","year":"2021","unstructured":"Pagano G.; Boess F.G.; Taylor K.I.; Ricci B.; Mollenhauer B.; Poewe W.; Boulay A.; Anzures-Cabrera J.; Vogt A.; Marchesi M.; Post A.; Nikolcheva T.; Kinney G.G.; Zago W.M.; Ness D.K.; Svoboda H.; Britschgi M.; Ostrowitzki S.; Simuni T.; Marek K.; Koller M.; Sevigny J.; Doody R.; Fontoura P.; Umbricht D.; Bonni A.; A Phase II study to evaluate the safety and efficacy of prasinezumab in early parkinson\u2019s disease (PASADENA): Rationale, design, and baseline data. Front Neurol  2021,12,705407","journal-title":"Front Neurol"},{"key":"ref=357","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"Pagano G.","year":"2022","unstructured":"Pagano G.; Taylor K.I.; Anzures-Cabrera J.; Marchesi M.; Simuni T.; Marek K.; Postuma R.B.; Pavese N.; Stocchi F.; Azulay J.P.; Mollenhauer B.; L\u00f3pez-Manzanares L.; Russell D.S.; Boyd J.T.; Nicholas A.P.; Luquin M.R.; Hauser R.A.; Gasser T.; Poewe W.; Ricci B.; Boulay A.; Vogt A.; Boess F.G.; Dukart J.; D\u2019Urso G.; Finch R.; Zanigni S.; Monnet A.; Pross N.; Hahn A.; Svoboda H.; Britschgi M.; Lipsmeier F.; Volkova-Volkmar E.; Lindemann M.; Dziadek S.; Holiga \u0160.; Rukina D.; Kustermann T.; Kerchner G.A.; Fontoura P.; Umbricht D.; Doody R.; Nikolcheva T.; Bonni A.; Trial of prasinezumab in early-stage parkinson\u2019s disease. N Engl J Med  2022,387(5),421-432","journal-title":"N Engl J Med"},{"key":"ref=358","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/psp4.12538","volume":"9","author":"Kuchimanchi M.","year":"2020","unstructured":"Kuchimanchi M.; Monine M.; Kandadi M.K.; Woodward C.; Penner N.; Phase I.I.; Phase II dose selection for alpha synuclein\u2013targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain. CPT Pharmacometrics Syst Pharmacol  2020,9(9),515-522","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=359","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"Lang A.E.","year":"2022","unstructured":"Lang A.E.; Siderowf A.D.; Macklin E.A.; Poewe W.; Brooks D.J.; Fernandez H.H.; Rascol O.; Giladi N.; Stocchi F.; Tanner C.M.; Postuma R.B.; Simon D.K.; Tolosa E.; Mollenhauer B.; Cedarbaum J.M.; Fraser K.; Xiao J.; Evans K.C.; Graham D.L.; Sapir I.; Inra J.; Hutchison R.M.; Yang M.; Fox T.; Budd Haeberlein S.; Dam T.; Trial of cinpanemab in early parkinson\u2019s disease. N Engl J Med  2022,387(5),408-420","journal-title":"N Engl J Med"},{"key":"ref=360","doi-asserted-by":"publisher","first-page":"104582","DOI":"10.1016\/j.nbd.2019.104582","volume":"132","author":"Schofield D.J.","year":"2019","unstructured":"Schofield D.J.; Irving L.; Calo L.; Bogstedt A.; Rees G.; Nuccitelli A.; Narwal R.; Petrone M.; Roberts J.; Brown L.; Cusdin F.; Dosanjh B.; Lloyd C.; Dobson C.; Gurrell I.; Fraser G.; McFarlane M.; Rockenstein E.; Spencer B.; Masliah E.; Spillantini M.G.; Tan K.; Billinton A.; Vaughan T.; Chessell I.; Perkinton M.S.; Perkinton M.S.; Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo. Neurobiol Dis  2019,132,104582","journal-title":"Neurobiol Dis"},{"key":"ref=361","doi-asserted-by":"publisher","first-page":"1994690","DOI":"10.1080\/19420862.2021.1994690","volume":"13","author":"Fjord-Larsen L.","year":"2021","unstructured":"Fjord-Larsen L.; Thougaard A.; Wegener K.M.; Christiansen J.; Larsen F.; Schr\u00f8der-Hansen L.M.; Kaarde M.; Ditlevsen D.K.; Nonclinical safety evaluation, pharmacokinetics, and target engagement of Lu AF82422, a monoclonal IgG1 antibody against alpha-synuclein in development for treatment of synucleinopathies. MAbs  2021,13(1),1994690","journal-title":"MAbs"},{"key":"ref=362","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3389\/fnins.2018.00452","volume":"12","author":"Kallab M.","year":"2018","unstructured":"Kallab M.; Herrera-Vaquero M.; Johannesson M.; Eriksson F.; Sigvardson J.; Poewe W.; Wenning G.K.; Nordstr\u00f6m E.; Stefanova N.; Region-specific effects of immunotherapy with antibodies targeting \u03b1-synuclein in a transgenic model of synucleinopathy. Front Neurosci  2018,12,452","journal-title":"Front Neurosci"},{"key":"ref=363","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.nbd.2021.105543","volume":"161","author":"Nordstr\u00f6m E.","year":"2021","unstructured":"Nordstr\u00f6m E.; Eriksson F.; Sigvardson J.; Johannesson M.; Kasrayan A.; Jones-Kostalla M.; Appelkvist P.; S\u00f6derberg L.; Nygren P.; Blom M.; Rachalski A.; Nordenankar K.; Zachrisson O.; Amandius E.; Osswald G.; Moge M.; Ingelsson M.; Bergstr\u00f6m J.; Lannfelt L.; M\u00f6ller C.; Giorgetti M.; F\u00e4lting J.; ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson\u2019s disease. Neurobiol Dis  2021,161,105543","journal-title":"Neurobiol Dis"},{"key":"ref=364","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.3390\/biomedicines10092168","volume":"10","author":"Gibbs E.","year":"2022","unstructured":"Gibbs E.; Zhao B.; Roman A.; Plotkin S.S.; Peng X.; Hsueh S.C.C.; Aina A.; Wang J.; Shyu C.; Yip C.K.; Nam S.E.; Kaplan J.M.; Cashman N.R.; Rational generation of monoclonal antibodies selective for pathogenic forms of alpha-synuclein. Biomedicines  2022,10(9),2168","journal-title":"Biomedicines"},{"key":"ref=365","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.3390\/vaccines10091527","volume":"10","author":"Valiukas Z.","year":"2022","unstructured":"Valiukas Z.; Ephraim R.; Tangalakis K.; Davidson M.; Apostolopoulos V.; Feehan J.; Immunotherapies for Alzheimer\u2019s disease: A review. Vaccines  2022,10(9),1527","journal-title":"Vaccines"},{"key":"ref=366","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","volume":"19","author":"Knecht L.","year":"2022","unstructured":"Knecht L.; Folke J.; Dodel R.; Ross J.A.; Albus A.; Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: A biological perspective. Neurotherapeutics  2022,19(5),1489-1502","journal-title":"Neurotherapeutics"},{"key":"ref=367","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1002\/mds.28218","volume":"35","author":"Meissner W.G.","year":"2020","unstructured":"Meissner W.G.; Traon A.P.L.; Foubert-Samier A.; Galabova G.; Galitzky M.; Kutzelnigg A.; Laurens B.; L\u00fchrs P.; Medori R.; P\u00e9ran P.; Sabatini U.; Vergnet S.; Volc D.; Poewe W.; Schneeberger A.; Staffler G.; Rascol O.; Anheim M.; Castrioto A.; Derkinderen P.; Drapier S.; Eusebio A.; Grabli D.; Marques A.; Moreau C.; Moro E.; Tranchant C.; A Phase 1 Randomized Trial of Specific Active \u03b1-SYNUCLEIN Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov Disord  2020,35(11),1957-1965","journal-title":"Mov Disord"},{"key":"ref=368","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/mds.29016","volume":"37","author":"Yu H.J.","year":"2022","unstructured":"Yu H.J.; Thijssen E.; van Brummelen E.; van der Plas J.L.; Radanovic I.; Moerland M.; Hsieh E.; Groeneveld G.J.; Dodart J.C.; A randomized first-in-human study with UB-312, a UBITh\u00ae \u03b1-synuclein peptide vaccine. Mov Disord  2022,37(7),1416-1424","journal-title":"Mov Disord"},{"key":"ref=369","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00401-021-02381-5","volume":"143","author":"Nimmo J.T.","year":"2022","unstructured":"Nimmo J.T.; Smith H.; Wang C.Y.; Teeling J.L.; Nicoll J.A.R.; Verma A.; Dodart J-C.; Liu Z.; Lin F.; Carare R.O.; Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric \u03b1-synuclein accumulation in the brain and gut. Acta Neuropathol  2022,143(1),55-73","journal-title":"Acta Neuropathol"},{"key":"ref=370","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/vaccines10091432","volume":"10","author":"Schmidhuber S.","year":"2022","unstructured":"Schmidhuber S.; Scheiblhofer S.; Weiss R.; Cserepes M.; T\u00f3v\u00e1ri J.; Gadermaier G.; Bezard E.; De Giorgi F.; Ichas F.; Strunk D.; Mandler M.; A Novel C-type lectin receptor-targeted \u03b1-synuclein-based parkinson vaccine induces potent immune responses and therapeutic efficacy in mice. Vaccines  2022,10(9),1432","journal-title":"Vaccines"},{"key":"ref=371","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s10072-012-1284-6","volume":"34","author":"Chen Z.","year":"2013","unstructured":"Chen Z.; Yang Y.; Yang X.; Zhou C.; Li F.; Lei P.; Zhong L.; Jin X.; Peng G.; Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson\u2019s disease. Neurol Sci  2013,34(9),1559-1570","journal-title":"Neurol Sci"},{"key":"ref=372","doi-asserted-by":"publisher","first-page":"104823","DOI":"10.1016\/j.nbd.2020.104823","volume":"139","author":"Petrushina I.","year":"2020","unstructured":"Petrushina I.; Hovakimyan A.; Harahap-Carrillo I.S.; Davtyan H.; Antonyan T.; Chailyan G.; Kazarian K.; Antonenko M.; Jullienne A.; Hamer M.M.; Obenaus A.; King O.; Zagorski K.; Blurton-Jones M.; Cribbs D.H.; Lander H.; Ghochikyan A.; Agadjanyan M.G.; Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. Neurobiol Dis  2020,139,104823","journal-title":"Neurobiol Dis"},{"key":"ref=373","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-021-00424-2","volume":"7","author":"Kim C.","year":"2022","unstructured":"Kim C.; Hovakimyan A.; Zagorski K.; Antonyan T.; Petrushina I.; Davtyan H.; Chailyan G.; Hasselmann J.; Iba M.; Adame A.; Rockenstein E.; Szabo M.; Blurton-Jones M.; Cribbs D.H.; Ghochikyan A.; Masliah E.; Agadjanyan M.G.; Efficacy and immunogenicity of MultiTEP-based DNA vaccines targeting human \u03b1-synuclein: Prelude for IND enabling studies. NPJ Vaccines  2022,7(1),1","journal-title":"NPJ Vaccines"},{"key":"ref=374","doi-asserted-by":"publisher","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","volume":"6","author":"Masliah E.","year":"2011","unstructured":"Masliah E.; Rockenstein E.; Mante M.; Crews L.; Spencer B.; Adame A.; Patrick C.; Trejo M.; Ubhi K.; Rohn T.T.; Mueller-Steiner S.; Seubert P.; Barbour R.; McConlogue L.; Buttini M.; Games D.; Schenk D.; Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One  2011,6(4),e19338","journal-title":"PLoS One"},{"key":"ref=375","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13195-020-00727-x","volume":"12","author":"Nimmo J.T.","year":"2020","unstructured":"Nimmo J.T.; Verma A.; Dodart J.C.; Wang C.Y.; Savistchenko J.; Melki R.; Carare R.O.; Nicoll J.A.R.; Novel antibodies detect additional \u03b1-synuclein pathology in synucleinopathies: Potential development for immunotherapy. Alzheimers Res Ther  2020,12(1),159","journal-title":"Alzheimers Res Ther"},{"key":"ref=376","doi-asserted-by":"publisher","first-page":"9441","DOI":"10.1523\/JNEUROSCI.5314-13.2014","volume":"34","author":"Games D.","year":"2014","unstructured":"Games D.; Valera E.; Spencer B.; Rockenstein E.; Mante M.; Adame A.; Patrick C.; Ubhi K.; Nuber S.; Sacayon P.; Zago W.; Seubert P.; Barbour R.; Schenk D.; Masliah E.; Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson\u2019s disease-like models. J Neurosci  2014,34(28),9441-9454","journal-title":"J Neurosci"},{"key":"ref=377","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/alzrt256","volume":"6","author":"Wang S.","year":"2014","unstructured":"Wang S.; Yu Y.; Geng S.; Wang D.; Zhang L.; Xie X.; Wu B.; Li C.; Xu H.; Li X.; Hu Y.; Zhang L.; Kaether C.; Wang B.; A coimmunization vaccine of A\u03b242 ameliorates cognitive deficits without brain inflammation in an Alzheimer\u2019s disease model. Alzheimers Res Ther  2014,6(3),26","journal-title":"Alzheimers Res Ther"},{"key":"ref=378","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12967-023-04012-x","volume":"21","author":"Xiao B.","year":"2023","unstructured":"Xiao B.; Tan E.K.; Immunotherapy trials in parkinson\u2019s disease: Challenges. J Transl Med  2023,21(1),178","journal-title":"J Transl Med"},{"key":"ref=379","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"Nicoll J.A.R.","year":"2019","unstructured":"Nicoll J.A.R.; Buckland G.R.; Harrison C.H.; Page A.; Harris S.; Love S.; Neal J.W.; Holmes C.; Boche D.; Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in Alzheimer\u2019s disease. Brain  2019,142(7),2113-2126","journal-title":"Brain"},{"key":"ref=380","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1021\/acschemneuro.2c00539","volume":"14","author":"Chu W.T.","year":"2023","unstructured":"Chu W.T.; Hall J.; Gurrala A.; Becsey A.; Raman S.; Okun M.S.; Flores C.T.; Giasson B.I.; Vaillancourt D.E.; Vedam-Mai V.; Evaluation of an adoptive cellular therapy-based vaccine in a transgenic mouse model of \u03b1-synucleinopathy. ACS Chem Neurosci  2023,14(2),235-245","journal-title":"ACS Chem Neurosci"},{"key":"ref=381","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1007\/s13311-020-00877-8","volume":"17","author":"Olson K.E.","year":"2020","unstructured":"Olson K.E.; Namminga K.L.; Schwab A.D.; Thurston M.J.; Lu Y.; Woods A.; Lei L.; Shen W.; Wang F.; Joseph S.B.; Gendelman H.E.; Mosley R.L.; Neuroprotective activities of long-acting granulocyte\u2013macrophage colony-stimulating factor (mpdm608) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice. Neurotherapeutics  2020,17(4),1861-1877","journal-title":"Neurotherapeutics"},{"key":"ref=382","doi-asserted-by":"publisher","first-page":"103380","DOI":"10.1016\/j.ebiom.2021.103380","volume":"67","author":"Olson K.E.","year":"2021","unstructured":"Olson K.E.; Namminga K.L.; Lu Y.; Schwab A.D.; Thurston M.J.; Abdelmoaty M.M.; Kumar V.; Wojtkiewicz M.; Obaro H.; Santamaria P.; Mosley R.L.; Gendelman H.E.; Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson\u2019s disease. EBioMedicine  2021,67,103380","journal-title":"EBioMedicine"},{"key":"ref=383","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41531-017-0013-5","volume":"3","author":"Gendelman H.E.","year":"2017","unstructured":"Gendelman H.E.; Zhang Y.; Santamaria P.; Olson K.E.; Schutt C.R.; Bhatti D.; Shetty B.L.D.; Lu Y.; Estes K.A.; Standaert D.G.; Heinrichs-Graham E.; Larson L.; Meza J.L.; Follett M.; Forsberg E.; Siuzdak G.; Wilson T.W.; Peterson C.; Mosley R.L.; Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson\u2019s disease trial. NPJ Parkinsons Dis  2017,3(1),10","journal-title":"NPJ Parkinsons Dis"},{"key":"ref=384","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.tmrv.2022.09.005","volume":"37","author":"Rohrer L.","year":"2023","unstructured":"Rohrer L.; Yunce M.; Montine T.J.; Shan H.; Plasma exchange in Alzheimer\u2019s disease. Transfus Med Rev  2023,37(1),10-15","journal-title":"Transfus Med Rev"},{"key":"ref=385","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/alz.12137","volume":"16","author":"Boada M.","year":"2020","unstructured":"Boada M.; L\u00f3pez O.L.; Olazar\u00e1n J.; N\u00fa\u00f1ez L.; Pfeffer M.; Paricio M.; Lorites J.; Pi\u00f1ol-Ripoll G.; G\u00e1mez J.E.; Anaya F.; Kiprov D.; Lima J.; Grifols C.; Torres M.; Costa M.; Bozzo J.; Szczepiorkowski Z.M.; Hendrix S.; P\u00e1ez A.; A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer\u2019s disease: Primary results of the AMBAR Study. Alzheimers Dement  2020,16(10),1412-1425","journal-title":"Alzheimers Dement"},{"key":"ref=386","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s11030-022-10452-2","volume":"27","author":"Singh S.","year":"2023","unstructured":"Singh S.; Kumar K.; Panda M.; Srivastava A.; Mishra A.; Prajapati V.K.; High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases. Mol Divers  2023,27(2),729-751","journal-title":"Mol Divers"},{"key":"ref=387","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12868-023-00782-8","volume":"24","author":"Liu Y.","year":"2023","unstructured":"Liu Y.; Meng Y.; Zhou C.; Yan J.; Guo C.; Dong W.; Activation of the IL-17\/TRAF6\/NF-\u03baB pathway is implicated in A\u03b2-induced neurotoxicity. BMC Neurosci  2023,24(1),14","journal-title":"BMC Neurosci"},{"key":"ref=388","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12974-022-02685-7","volume":"19","author":"Badr M.","year":"2022","unstructured":"Badr M.; McFleder R.L.; Wu J.; Knorr S.; Koprich J.B.; H\u00fcnig T.; Brotchie J.M.; Volkmann J.; Lutz M.B.; Ip C.W.; Expansion of regulatory T cells by CD28 superagonistic antibodies attenuates neurodegeneration in A53T-\u03b1-synuclein Parkinson\u2019s disease mice. J Neuroinflammation  2022,19(1),319","journal-title":"J Neuroinflammation"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231017141636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/222281\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X22666231017141636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T05:41:28Z","timestamp":1711345288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/222281\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":388,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x22666231017141636","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}